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1CHAPTER I 
 
INTRODUCTION 
 
BACKGROUND 
 The agricultural industry has exponentially expanded within the last 100 years.  
This advancement has been made possible through the work of scientists, researchers, 
engineers, mechanics, corporations, and government officials.  The list of contributions is 
very large.  Crops are now produced in massive quantities to meet the increasing demand 
of the world’s population.  Currently, food production surpasses the world population, 
but due to uneven distribution, the need still remains for more efficient technologies 
(USDA, 2005).  A large factor involved in the uneven food-population distribution is the 
quantity and quality of the inputs used for the food production industry.  These inputs 
include land, natural resources (water, etc.), industrial resources such as mechanization 
and facility, and in the case of food animal production, grain production is vital to 
establish success (USDA, 2002).  Agriculture has been able to grow and expand due to 
the necessity of a larger industry.  The days of small scale production are now almost 
exclusively part of the world’s (especially the US) past.  Large-scale production is the 
forefront for the future of the agricultural industry. 
2GLOBAL PRODUCTION 
 On the global scale, the agricultural production industry relies on the inputs 
needed to achieve success.  The animal production industry especially relies on available 
nutrient input.  The most important inputs for meat production include capital, feed, and 
labor.  The regions of the world that can most efficiently supply these resources will be 
able to generate the most product (Dyck et al., 2003).  As these resources grow and 
become more available throughout the world, meat consumption will increase on a global 
scale. 
 The poultry industry can be a direct model for the increase of production with 
increased resources.  The poultry industry has grown and become very successful 
because of both low-cost labor and the availability of feed products from close proximity 
production.  The industry has also flourished globally because the meat is produced and 
available at a lower cost than pork or grain-fed beef.  This fact means less capital is 
required to produce a valuable protein source (Dyck et al., 2003). 
 Because poultry meat is cheaper to produce compared with pork and grain-fed 
beef, the global consumption of poultry has increased in recent years.  Poultry meat 
consumption per capita grew faster in all three classes of countries (high-, middle-, and 
low-income) than the consumption of all other meats between 1961 and 2000.  This 
increase was 370, 635, and 201 percent for high-, middle-, and low-income countries, 
respectively.  Although total meat consumption per capita increased worldwide, it is clear 
that poultry meat consumption was significantly higher than the other meat products 
(Taha, 2001). 
3POULTRY INDUSTRY ADVANCEMENT 
 The 20th century has proven to be an era of incredible growth for the poultry 
industry.  The most growth and prosperity has occurred over the past 50-75 years (Etches, 
1998, Hammerstedt, 1999, and Rishell, 1997).  The success of the industry has come 
from the efforts of the scientific community to incorporate biological knowledge and 
discovery into the production of a fast-growing broiler chicken.  Particular credit can be 
given to the focus of scientists on the metabolic processes occurring at a molecular level 
in animals.  The discoveries resulting from such focus also resulted in the development of 
a massive biochemical and pharmaceutical industry.  The advancements made by all of 
these contributors have allowed the industry to develop from the small, “backyard” farm 
into the current production schemes that incorporate large amounts of both mechanical 
and biological technology to run large, commercial farms capable of producing thousands 
of broilers every year.  Because of the expansion, poultry meat is now the most 
commonly consumed meat in many diets the world over (Etches, 1998). 
 The advancements seen in biology have also led to dramatic improvement 
through genetic study.  The industry has benefited from improved genetic selection 
through the last 50 years (Rishell, 1997).  Geneticists are able to study the chickens based 
on discoveries in biology to select birds that will produce offspring able to develop into 
the desired end product.  Although much of the industry’s success has been attributed to 
genetic development, the chickens could not perform to their highest potential without 
proper environmental conditions.   
The role of the nutritionist, farm manager, and veterinarian is to assure that the 
genetic potential of the chicken can be achieved through proper management.  It is quite 
4clear that these workers in the industry have also helped the industry progress.  Using the 
discoveries of others within the industry, these contributors will be able to provide the 
proper diet to achieve the metabolic potential of the bird or provide the proper protection 
against disease in the environment.  The scientists within the industry have performed 
quite well in terms of advancement.  One study by Havenstein et al. (2003) compared the 
carcass compositions of birds eating a typical diet from 1957 to one from 2001.  The 
study used two separate lines of birds common to each time period.  The birds consuming 
the 2001 diet were superior to the 1957 birds in terms of carcass weights, hot carcass 
yield, breast meat yield, saddle and leg yield, and whole carcass fat yield.  The study 
shows that the typical broiler has increased in size over time yielding more end product to 
be sold (Havenstein et al., 2003).  This fact has been achieved thanks to the combined 
efforts of the geneticists, nutritionists, biochemists, veterinarians, etc.  
 
POULTRY MEAT PRODUCTION IN THE U.S.      
 Poultry production in the U.S. is higher than any other area in the world.  The 
total farm value is greater than $20 billion.  The U.S. is second to Brazil in broiler export 
(USDA, 2006).  This fact demonstrates the need and use of broiler products within the 
U.S.  The annual production of broilers has steadily increased over the years.  Between 
2004 and 2006, the production of broilers rose from 34,063 million pounds in 2004 to 
35,799 million pounds in 2006.  The annual production of both beef and pork has also 
risen over the past 3 years, but poultry meat still far exceeds those industries.  In 2006, 
beef production reached 26,075 million pounds, and pork production reached 21,010 
million pounds.  In 2006, the USDA recorded an annual per capita consumption of broiler 
5meat to be 87.4 pounds while pork slightly decreased from 50 pounds in 2005 to 49.2 in 
2006.  Beef per capita consumption was 65.6 pounds in 2006.  The projected total for all 
three meats shows a suspected increase in 2007 for both categories with the exception 
that broiler per capita consumption will decrease slightly to 86.4 pounds.  Broilers will 
still remain the highest in both categories (USDA, 2007).  One can clearly see from these 
numbers that broiler meat is in high demand in the U.S.  Broiler meat is in high demand 
because of the lower cost of it compared with beef (USDA, 2007).  Also, broiler meat is 
readily available almost anywhere in the country.   
The industry must strive to meet the increasing demand for poultry products.  The 
importance of healthy birds becomes clear after viewing the statistics.  Without the ability 
to produce a valuable end product, the industry would surely fail.  To obtain that product, 
the industry must have the proper growth and development of the chickens.  The birds 
must be healthy through proper management to achieve the required growth.  From the 
scientific community, proper management techniques can be tested to provide the best 
environment for the chickens to reach their potential.  One area of major concern that 
may retard the growth of chickens is disease.  Scientists have studied and developed 
medications and vaccines to fight diseases of all kinds.  Today, techniques to fight 
disease are employed all over the world to aid the industry’s effort to produce healthy 
chickens ensuring the continuation of the success of the industry.  New techniques and 
new methodologies to use the current techniques are constantly developing to further 
improve industry products. 
 
6REFERENCES 
 
Agriculture at the crossroads:  Energy, farm and rural policy.  2007.  Agricultural  
Outlook Forum 2007.  Economic Research Service, United States Department of 
Agriculture. 
 
Dyck, J.H. and K.E. Nelson.  2003.  Structure of the global markets for meat.   
Agricultural Information Bulletin No. 785, Economic Research Service, United 
States Department of Agriculture. 
 
Etches, R.J.  1998.  Gordon memorial lecture.  A holistic view of poultry science  
from a reductionist perspective.  British Poultry Science 39:5-10.   
 
Global resources and productivity.  2005.  Economic Research Service, United States  
Department of Agriculture http://www.ers.usda.gov/Briefing/GlobalResources/. 
 
Global resources and productivity:  Questions and answers.  2002.  Economic  
Research Service, United States Department of Agriculture 
http://www.ers.usda.gov/Briefing/GlobalResources/Questions/grq1.htm. 
 
Hammerstedt, R.H.  1999.  Symposium summary and challenges for the future.   
Poultry Science 78:459-466. 
 
Havenstein, G.B., P.R. Ferket, and M.A. Qureshi.  2003.  Carcass composition and  
yield of 1957 versus 2001 broilers when fed representative 1957 and 2001 broiler 
diets.  Poultry Science 82:  1509-1518. 
 
Poultry and eggs.  2006.  Economic Research Service, United States Department of  
Agriculture http://www.ers.usda.gov/Briefing/Poultry/. 
 
Rishell, W.A.  1997.  Breeding and genetics.  Symposium:  Genetic selection-  
strategies for the future.  Breeding and genetics-historical perspective.  Poultry 
Science 76:1057-1061. 
 
Taha, F. A. 2001. The Poultry Sector in Middle-Income Countries and It’s Feed  
Requirements. The Case of Egypt. U.S. Department of Agriculture, Economic 
research unit USDA 1-42. 
 
7CHAPTER II 
REVIEW OF LITERATURE 
 
COCCIDIOSIS 
 Coccidiosis is a disease that is commonly seen in many different species of 
animal.  It is a general term given to a set of diseases caused by parasites that affects the 
intestinal tract causing the same symptoms and results.  In the poultry industry, it is 
among the top reported diseases making it of high importance (Williams, 2002b).  In 
chickens the disease is characterized by a quick onset of bloody diarrhea with high 
mortality rate.  It is caused by an infection of the intestinal tract with the protozoan 
parasites of the genus Eimeria (Allen et al., 1997, Chapman, 2000, Chapman, 2001, 
Dalloul et al., 2005, Korver et al., 1997, Lillehoj et al., 2000, McDougland et al., 1991, 
Medarova et al., 2003, Williams, 2002b, and Yaissle et al., 1999). The three potentially 
pathogenic species of high concern are E. acervulina, E. maxima, and E. tenella 
(Chapman, 2000).  A total of nine species have been discovered from chickens with 
seven of those nine possessing the confirmed ability to be a parasite to chickens (Allen et 
al., 2002, Chapman, 2000, Dalloul et al., 2005, Lillehoj et al., 2000, and McDougland et 
al., 1991). These protozoa are species specific.  They are so specific that if one wished to 
observe coccidiosis in turkeys, the parasites from infected chickens could not be used to 
induce the disease in turkeys.  The oocysts that result from chicken infection cannot 
infect turkeys.  Therefore, the disease cannot be brought into a house from wild fowl.  
8Most often, transportation of the parasites results from the interaction of people with 
infected chickens.  The people then transport the parasites between chicken houses within 
a farm (C. Broussard, Schering Plough Animal Health, personal communication and 
Lillehoj et al., 2000).   
The different strains of Eimeria affect different regions of the intestinal tract.  
Some of the species will attack the upper small intestine while others may attack the mid 
small intestine and the ceca.  Eimeria acervulina, E. mivati, E. praecox, and E. hagani 
infect the upper small intestine.  Eimeria maxima and E. necatrix infect the mid portion 
of the small intestine with some spillage into both the upper and lower portions with the 
most prominent infection remaining in the mid small intestine.  Eimeria brunetti, E. mitis, 
and E. tenella infect the lower small intestine/ceca region (Allen et al., 2002, Dalloul et 
al., 2005, Lillehoj et al., 2000, and McDougland et al., 1991).  Once in the host, the 
protozoa quickly multiply in the intestinal tract.  The infection causes tissue damage 
which will affect digestion and absorption within the intestine, and hence, decrease 
performance.  Eventually, the disease will lead to dehydration and blood loss.  The 
disease typically occurs in young animals because exposure aids in immune development 
against further infection (McDougland et al., 1991).    
 Coccidiosis is a significant disease because of the rapid turnaround of the 
infection.  The parasites that cause coccidiosis undergo a very short life cycle.  Because 
of the short life cycle, an entire house can become infected in a very short period of time.  
It is also significant because every year it costs the industry an estimated $800 million in 
losses (Dalloul et al., 2005).  This estimated cost considers the prevention medication, 
treatment medication, and losses due to mortality, inefficient feed utilization, temporary 
9reduction of egg production, malabsorption, and impaired growth rate (Dalloul et al., 
2005). 
 
LESION SCORING  
Coccidiosis in the field must be determined by observation of malabsorption, 
reduced growth, bloody diarrhea, and litter sampling to determine oocyst numbers.  
Unfortunately, when the symptoms associated with coccidiosis are severe enough to be 
observed, the entire crop may be infected.  A useful tool used in research areas to assess 
the severity of coccidial infection is lesion scoring.  Gross lesion scores are used in many 
trials involving coccidiosis to obtain an understanding of the severity of coccidial 
infection.  The typical lesion scoring techniques were reviewed by Johnson and Reid 
(1970) and this review set the standard for future scoring within the poultry industry.   
 Because of the organ specificity of the different species of Eimeria discussed 
earlier, the gastrointestinal tract of the supposedly infected bird must be examined at 
multiple points.  There are four suggested regions of the small intestine that are of major 
concern.  These regions include the upper section of the small intestine including the 
duodenal loop, the mid small intestine that is located above and below the yolk sac 
diverticulum, the lower intestine including the rectum, and cecal tonsil, and the ceca 
itself.  The gross lesion scoring system was based on a scale ranging from 0 to +4 with 
the level of infection increasing with number.  The system also varied from species to 
species in terms of visual observations because of the varying reactions to the different 
species (Johnson et al., 1970). 
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The study (Johnson et al., 1970) reviewed and established scoring procedures for 
the species E. tenella, E. necatrix, E. acervulina, E. mivati, E. maxima, and E. brunetti. 
The study reviewed former systems and establishes its own based on studies performed 
by Johnson and Reid (1970), although the studies were not described in high detail.  
Because the only microorganisms considered for my study are E. tenella, E. acervulina, 
and E. maxima only the scoring for those species will be described in detail, but the other 
species will be briefly mentioned in terms of first score recording.  A study performed by 
Herrick et al. (1942) was the first recorded scoring for E. tenella using a numerical 
system from 0 to +4.  The study defined the different levels as follows:  0 = no lesions; 
+1 = very few lesions; +2 = “slight” lesions; +3 = considerable blood present with many 
lesions; and +4 = severe lesions and large quantity of blood.  That system was followed 
by many researchers with some altering the system slightly by adding a +5 score, 
removing the +4 score, or more specifically, defining the scores (Johnson et al., 1970).  
Because E. tenella is specific to the ceca of chickens, this region is the region scored for 
infection with the species.  Johnson and Reid (1970) determined scoring specifications to 
be the following for E. tenella:
“0  No gross lesions. 
 +1  Very few scattered petechiae on the cecal wall; no thickening of the cecal  
 walls; normal cecal contents present. 
 +2  Lesions more numerous with noticeable blood in the cecal contents; cecal  
 wall is somewhat thickened; normal cecal contents present. 
 +3  Large amounts of blood or cecal cores present; cecal walls greatly thickened;  
 little, if any, fecal contents in the ceca. 
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+4  Cecal wall greatly distended with blood or large caseous cores; fecal debris  
 lacking or included in cores.  Dead birds scored as +4.”        
 Johnson and Reid (1970) also detailed the various studies that led to the 
development of the scoring systems for the various species of Eimeria.  The first time 
scores for these various species were defined and recorded vary over time.  Eimeria 
necatrix was first scored by Cuckler et al. in 1956, but the most detailed scoring before 
Johnson and Reid (1970) was performed in 1968 by Dunkley. Eimeria mivati is very 
similar to E. acervulina, so the scoring system to be described for E. acervulina may be 
used with the following exceptions:  late infections may move toward the posterior 
portion of the small intestine, the shape is round contrasting the ladder shape of E. 
acervulina, and the severe congestion typical of E. acervulina has not been seen.  E. 
acervulina scoring was first recorded by Cuckler (1957).  Johnson and Reid (1970) 
devised a system considering the following criteria for each score: 
“0  No gross lesions.   
+1  Scattered, white plaque-like lesions containing developing oocysts are  
 confined to the duodenum.  These lesions are elongated with the longer axis  
 transversely oriented on the intestinal walls like the rungs of a ladder.  They  
 may be seen from either the serosal or mucosal intestinal surfaces.  They may  
 range up to maximum of 5 lesions per square centimeter.   
+2  Lesions are much closer together, but not coalescent; lesions may extend as  
 far posterior as 20 cm below the duodenum in 3-week-old birds.  The  
 intestinal walls show no thickening.  Digestive tract contents are normal.   
+3  Lesions are numerous enough to cause coalescence with reduction in lesion  
12
size and give the intestine a coated appearance.  The intestinal wall is  
 thickened and the contents are watery.  Lesions may extend as far posterior as  
 the yolk sac diverticulum.   
+4  The mucosal wall is grayish with colonies completely coalescent.  Congestion  
 may be confined to small petechiae or, in extremely heavy infection, the entire  
 mucosa may be bright red in color (Morehouse and McGuire 1958).   
 Individual lesions may be indistinguishable in the upper intestine.  Typical  
 ladder-like lesions appear in the middle part of the intestine.  The intestinal  
 wall is very much thickened, and the intestine is filled with a creamy exudate  
 which may bear large numbers of oocysts.  Birds dying of coccidiosis are  
 scored as +4.”  
Rose (1967) was the first to record scores for E. brunetti, but she provided no 
descriptions of the scores or criteria for scores.  Before her study, E. brunetti had been 
described and studied, but no scored.  Johnson and Reid (1970) used Levine’s (1942) 
descriptions to establish scoring criteria for E. brunetti.   Eimeria maxima proved to be a 
difficult species to score due to the fact that not much work existed before Johnson and 
Reid’s in 1970 and the fact that the few records available provided little details and 
varying results.  Their work concluded the following system: 
 “0  No gross lesions. 
 +1  Small red petechiae may appear on the serosal side of the mid-intestine.   
 There is no ballooning or thickening of the intestine, though small amounts of  
 orange mucus may be present.   
+2  Serosal surface may be speckled with numerous red petechiae; intestine may  
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be filled with orange mucus; little or no ballooning of the intestine; thickening  
 of the wall.   
+3  Intestinal wall is ballooned and thickened.  The mucosal surface is roughened;  
 intestinal contents filled with pinpoint blood clots and mucus.   
+4  The intestinal wall may be ballooned for most of its length; contains  
 numerous blood clots and digested red blood cells giving a characteristic color  
 and putrid odor; the wall is greatly thickened; dead birds are recorded with  
 this score.”  
 Johnson and Reid (1970) decided that scoring individual species was too difficult.  
Because of the fact that Eimeria species are specific to certain regions of the GI tract, 
they concluded that species could be narrowed between a few likely to inhabit the area of 
study.  They also mentioned the importance of microscopic scoring to better determine 
species and to assure that the visual signs are resulting from Eimeria induced coccidiosis 
instead of some other parasitic affliction.  The authors proceeded to describe their 
recommendations for proper scoring involving slide smearing for microscopic scores, 
guidelines to ensure accurate data collection (blind scorer ignorant to treatments, etc.), 
and proper representative numbers to be scored.   
 
NUTRITIONAL APPROACHES 
 Since the discovery of coccidiosis in poultry, the industry has spent large sums of 
money to treat and prevent it with the hope of one day completely eradicating the disease.  
One area of interest in the fight against coccidiosis is nutrition.  Studies have been 
performed changing various aspects of nutrition to hopefully discourage the disease.  
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Nutrition is an area of high interest because it has the ability to impact the animals’ 
performance in so many ways.   
Because coccidiosis attacks the intestinal tract where nutrients are absorbed, 
nutrition should be a primary route for the prevention of the disease.  The organisms that 
cause the disease live in the intestinal tract.  They directly interact with the feed ingested 
by the birds.  Utilizing this fact, scientists have attempted to alter nutrition to fight the 
disease.  Even though no miracle nutritional additive (antimicrobials excluded) has been 
discovered to combat coccidiosis, researchers will always be searching for the ingredient 
to destroy coccidiosis without the risk of any adverse effects on feed consumption or 
nutrient absorption. 
 Vitamin E is an essential nutrient for chicken growth and development.  It is 
commonly known to be an antioxidant.  It protects against free radical oxidative 
processes such as the formation of hydrogen peroxide which is fatal to many animals.  
Vitamin E is also known to be an immunomodulator in chickens.  Vitamin E has been 
reported to be able to boost humoral responses to E. coli infection when supplied in high 
amounts, and it increased body weight gains and reduced lesion scores in chickens that 
were challenged with E. tenella (Allen et al., 2002).   
Allen et al. (2002) conducted a study to investigate if supplementation with high 
levels of dietary vitamin E (DL-F-tocopheryl acetate; VE-AC) would counteract the 
pathological effects of infection with E. maxima. The study was conducted on Ross-
based roaster chickens supplied with varying levels of VE-AC that provided the 
experiment with five treatments ranging from 13.2 ppm vitamin E to 200 ppm vitamin E 
in 2 trials (Trial 1:  13.2 ppm, 27.4 ppm, 39.8 ppm, 76 ppm, and 153 ppm; Trial 2:  13.2 
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ppm, 25 ppm, 50 ppm, 100 ppm, and 200 ppm).  Two strains of E. maxima were used as 
challenge material.  During Trial 1, 15 birds were randomly assigned to infected group 
and 15 were assigned to control group on day 22 of the trial.  Chickens in the infected 
group were inoculated with 175,000 sporulated oocyst/Ml of lab Strain ESS.  Chickens 
used in Trial 2 were randomly assigned to receive one of the five levels of VE-AC.  On 
day 14, chickens were assigned to infected or control groups.  The infected group 
received a dose of 40,000 sporulated oocysts of the Guelph strain of E. maxima (Allen et 
al., 2002). 
 Trial 1 showed no differences between the birds receiving various levels of VE-
AC in terms of mean body weights.  The increased levels of VE-AC did not effect weight 
gain or feed conversion of the uninfected chickens.  Only the mean gain 6 days post 
infection for the birds receiving 76 ppm VE-AC was significantly decreased compared to 
the controls.  The lesion scores decreased numerically with increasing VE-AC levels, but 
the only statistical difference noted was between the 0 ppm level and the 153 ppm level 
(Allen et al., 2002). 
 During Trial 2 (a more severe E. maxima infection), the uninfected control 
birds showed no differences in weight gain at different VE-AC levels.  The infection 
caused decreased weight gain in all levels of VE-AC supplementation.  The chickens that 
were given 100 and 200 ppm VE-AC and infected with the Guelph strain had 
significantly lower weight gains than those given 13.2 ppm and infected with Guelph 
strain.  Varying levels of VE-AC did not have any effect on lesion scores.  They 
concluded that supplementation with up to 200 ppm of VE-AC did not produce the 
hypothesized result of reducing the negative effects of E. maxima infection.  The 
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infection may have led to malabsorption of supplements leading to the lack of VE-AC 
effect.  They also believed that an issue involving lipid absorption may have interfered 
with the VE-AC effect, and increased intestinal mucosal cell turnover commonly seen 
during coccidian infection may have attributed to the VE-AC ineffectiveness.  The final 
conclusion they reached was that increasing amounts of VE-AC supplementation did not 
increase antioxidant protection in chickens infected with E. maxima. Their most 
reasonable explanation for this fact was that lipid malabsorption occurred during the 
infection.  This led to the inability of the dietary vitamin E to access the infected tissue 
and provide aid. 
Nitric oxide (NO) is known to have antimicrobial activity.  The amino acid, L-
arginine, is the substrate for biosynthesis of NO (Allen, 1999).  During an immunological 
response to some infection, induced NO synthase (Inos) may be stimulated and will lead 
to biosynthesis of NO.  NO levels in plasma (ions NO2- and NO3-) were previously found 
to increase during infection with E. tenella, E. acervulina, and E. maxima.  Because of 
this, Allen (1999) has proposed that dietary levels of L-arginine should influence the 
production of NO as a response to immunological infection, specifically, coccidiosis.  
She conducted two experiments to determine if L-arginine was able to influence the 
development or pathology of the coccidian parasites. 
During experiment 1, Allen (1999) divided the chickens into six groups at three 
weeks of age.  Three of the six groups of chickens were given a daily dose of L-arginine 
(500 mg/kg) beginning 1 day prior to infection through 8 days post infection.  The other 
three groups were not dosed with L-arginine.  Each set of three groups contained one 
group inoculated with 30,000 sporulated oocysts of E. maxima, one group inoculated 
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with 50,000 sporulated oocysts of E. tenella, and one group not inoculated.  This 
procedure was repeated for experiment 2 with a few alterations.  The birds dosed with L-
arginine were given two daily doses of L-arginine (500 mg/kg) instead of just one.  The 
birds that were inoculated with oocysts were inoculated with either 500,000 sporulated 
oocysts of E. acervulina or 25,000 sporulated oocysts of E. tenella strain MS (Allen, 
1999). 
During experiment 1, the infection with E. tenella significantly reduced weight 
gain whether or not the birds had been treated with L-arginine.  The infection with either 
of the oocysts increased plasma NO2- + NO3-. L-arginine treatment had no effect on 
weight gain, lesion scores, or plasma NO2- + NO3-. In the birds infected with E. maxima,
arginine did not affect oocyst shedding, but those infected with E. tenella experienced a 
26% reduction in oocyst shedding when treated with L-arginine.  In experiment 2, 
infection with each organism significantly reduced weight gain and increased plasma 
NO2- + NO3- levels regardless of treatment with L-arginine (dosed or not).  The results for 
experiment 2 resemble those of experiment 1 with the only advantage of L-arginine being 
that it reduced E. tenella oocyst shedding by 39%.  L-arginine had no effect on lesion 
scores, weight gain, E. acervulina oocyst shedding, or plasma NO2- + NO3- levels.   
The inhibition of E. tenella suggests that the arginine acts specifically on sites 
where E. tenella is likely to develop instead of those containing E. maxima and E. 
acervulina. Because the arginine did not affect weight gain, she suggested that the L-
arginine “was not a rate-limiting factor for growth in infected chickens”.  She concluded 
that the supplementation with additional L-arginine provided no benefit during a 
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coccidial infection when it was already provided in the diet besides the inhibition of E. 
tenella development (Allen, 1999).   
Yaissle et al. (1999) designed a study to investigate the interaction of dietary 
protein levels with coccidiosis infection in feed-restricted pullets.  Literature reported 
before this study had conflicting conclusions regarding the effects of dietary protein on 
chickens during coccidial infection.  A few of the reported studies exhibited contradictory 
results where added dietary protein acted to aid the birds to better cope with the 
coccidiosis infection.  Other investigators suggested that higher dietary protein 
exacerbated the severity of the coccidial infection.    
Yaissle et al. (1999) conducted two experiments to investigate dietary protein 
level effect on coccidial infection lasting 28 days.  During experiment 1, two dietary 
levels of protein (15% CP and 19% CP) and three levels of vaccine dose (H2O; 1X; 4X) 
were used creating a 2 x 3 factorial arrangement of treatments.  The vaccine was 
administered as control (H2O only), 1X (1000 Ml 4X mixed with 3000 Ml H2O), or 4X 
(one vial Coccivac-D® mixed with 3000 Ml H2O).  The vaccine was administered to all 
birds on day 7.  On day 7 the birds were started on an every-other-day (EOD) feeding 
schedule receiving 45 g of feed EOD until 21 days.  The birds were fed 68 g EOD from 
21 to 28 days.  The same procedure was used for experiment 2 except birds were placed 
on the EOD feeding schedule on day 10.  They were given 55 g of feed EOD until 21 
days when the feed was increased to 78 g thereafter.  The vaccine was administered on 
day 4 instead of day 7. 
During experiment 1, no significant differences were observed between the 
varying levels of vaccination.  Body weight and pectoralis major muscle weights were 
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significantly increased at 14 and 21 d post vaccination in the birds that received the 19% 
CP diet compared to those given the 15% CP diet.  No clinical signs of coccidiosis were 
present in experiment 1 or experiment 2.  The birds in experiment 2 that received 1X and 
4X vaccine doses, regardless of protein level, both exhibited mucosal lesions present in 
the duodenum.  The mucosal cells of the villi of both vaccine groups (1X and 4X) fed 
both diets were infiltrated by oocysts, macrogametes, and microgametes.  The infiltration 
was more severe in the birds that had received the 4X dosage.  The pullets given the 1X 
dosage were significantly heavier than the 4X birds at 28 d of age.  Protein level at this 
stage had no effect on body weight.  The results reported here reveal that increasing 
dietary protein level may enhance the birds’ ability to cope with a coccidial infection, but 
it will most likely have no effect on the intestinal health of the infected birds (Yaissle et 
al., 1999).   
Another approach taken by Korver et al. (1997) involved supplying broilers with 
identical diets except for the use of either corn oil or fish oil as ingredients.  In addition to 
the two oils, the inclusion or exclusion of Lofrin and infection with Eimeria tenella 
oocysts were used as treatments.  The use of fish oil numerically increased the growth of 
the broilers throughout the trial compared to corn oil.  Infection of the broilers with 
Eimeria did not significantly affect the body weight gain over diet and Lofrin treatments.  
The challenge was either not severe enough or long enough to affect the broilers.  
However, there was a diet by infection interaction observed because the birds receiving 
the corn oil diet had decreased body weight when infected compared to the broilers given 
the fish oil diet.  Within the corn oil diet groups, Lofrin decreased the negative effects of 
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the infection.  The corn oil diets were the only groups that differed in body weight gain 
due to infection and Lofrin inclusion (Korver et al., 1997).   
The broilers consuming the fish oil diet had a higher feed intake than those eating 
the corn oil diet.  The birds consuming corn oil had decreased feed intake from day 15 to 
23 when given Lofrin.  The fish oil birds did not decrease feed intake when given Lofrin.  
Lofrin was shown to increase feed conversion efficiency (FCE) of the chickens fed the 
corn oil diet, but the ones eating the fish oil diet had no change when fed the Lofrin 
supplemented diet.  The infected birds fed corn oil exhibited a decreased FCE, but no 
decrease was present in the birds fed fish oil and infected.  Lofrin also acted to inhibit the 
negative effect of the coccidial infection on FCE.  When it was present FCE did not 
decrease, but when it was not present, the FCE was decreased by the Eimeria infection 
(Korver et al., 1997).   
Overall, substituting fish oil for corn oil or using Lofrin with corn oil decreased 
the negative effects of a coccidial challenge.  The use of Lofrin or fish oil could aid the 
broiler in defense against the possibly disastrous effects seen during a coccidial 
challenge.  Using fish oil and Lofrin together had no additive effect in the challenged 
broilers.  The mechanisms that produced the increased performance associated with using 
either product are not yet known.  The PUFA from fish oil is believed to decrease the 
coccidial infection effects on growth, and the Lofrin acts to block the 5-LO pathway 
possibly aiding the birds’ performance (Korver et al., 1997).             
New techniques and substances are being developed and tested constantly to 
control the instances of coccidial infections in the poultry industry.  Many efforts are 
being made to use “natural” solutions to avoid the use of pharmaceutical controls.  
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Because coccidiosis mainly affects the digestive tract, the most reasonable course of 
action is through dietary manipulation.  The substitution of typical ingredients with those 
that may inhibit the development of the pathogens or increase the bird’s ability to cope 
with the challenge is commonly undergone to reduce the loss associated with coccidial 
infections.  All of the research involved in discovering these new ingredients and 
techniques are aimed at realizing a cost-effective and safe means of completely 
controlling or even eliminated the disease.  The approach taken to use the dietary 
manipulation using the “natural” sources comes from the belief that the process of using 
drugs and vaccines will eventually become outlawed.  
 
ANTICOCCIDIALS 
 The development of chemotherapy against disease is believed to have begun with 
Paul Ehrlich.  He developed a compound that was used to treat syphilis.  After his success 
in 1909, many other researchers began the quest to develop new treatments against many 
diseases that had plagued humans since the beginning of time.  Alexander Fleming was 
the man who led the effort to kill harmful microorganisms within the human body.  He 
was successful when he discovered penicillin to kill staphylococci in 1928.  Fleming’s 
work was dismissed by many of his colleagues because the penicillin was derived from 
mold, but others looked to his studies as inspiration to join the fight against harmful 
microorganisms (Jones et al., 2003).   
The development of many more antibiotics followed the early research, and now 
antibiotics are used all over the world for humans and animals alike.  In fact, today 
antibiotics are often abused.  Patients visiting their family doctors demand antibiotics 
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because the antibiotics have made them feel better in the past when they experienced a 
bacterial infection, but if they are infected with viruses, then they are only hurting 
themselves. 
During the 1940s, the use of animal protein to feed poultry declined.  The animal 
protein was not available to supply the poultry industry, so vegetable protein was used.  
The industry was expanding, but the supply was lacking.  The performance observed in 
poultry and swine declined when vegetable protein was used in place of animal protein.  
The industries determined that an unknown factor was present in animal protein that was 
necessary to provide the poultry and swine with proper nutrition.  It was aptly named 
animal protein factor (APF).  Research began to determine the specifics behind the factor 
to aid the industries in the time of short supply (Jones et al., 2003).   
In 1948, Rickes et al. and Ott et al. published reports that confirmed that vitamin 
B12 was the APF that was needed in those diets.  The research performed when 
determining APF led to the discovery that other feed ingredients acted as the B12 in terms 
of growth promotion.  Some of the other ingredients also had improved growth 
promotion above that of B12. One such constituent was fungal mycelia, more 
specifically, antibiotics found in the mycelia.  Many researchers performing studies on 
pigs and chickens around this time were able to show that the inclusion of antibiotics in 
feed promoted increased growth.  The research of these individuals and groups led to the 
approval of the routine use of antibiotics in animal feed by the FDA in 1951 (Jones et al., 
2003).     
In 2002, the Feed Additive Compendium listed 32 antimicrobial compounds that 
are allowed for use in the feeds given to broilers in the United States without veterinary 
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prescription (Jones et al., 2003; Miller Publishing Company, 2001).  Many of the 
compounds are used from early in the production cycle until a predetermined withdrawal 
time to remove any residue that would possibly remain after slaughter.  They are used 
even when the producer has observed no signs of the microbial infection in his birds.  
Eleven of the antibiotics are used and classified as growth promoters to help the birds 
cope with any possible infection that may occur and to reduce the chance of an infection.  
The growth promoters are aptly named because they typically improve the birds’ 
performance in terms of weight gain and feed efficiency by the prevention of microbial 
challenge when the microbe is present. 
Fifteen of the 32 compounds on the list are anticoccidials (Jones et al., 2003).  
They are produced to fight coccidiosis in the commercial poultry industry.  
Anticoccidials make up the largest class of antimicrobial compound on the list.  This 
demonstrates how important of a disease coccidiosis has become, and it shows the 
tremendous amount of time and effort that has been devoted to the control of coccidiosis 
throughout the years.   
Today, most of the broilers raised in the U.S. in the commercial industry are done 
so with an anticoccidal drug administered in the feed.  In fact, a study by Chapman 
(2001) showed that from 1995 though 1999, 99% of the poultry plants (comprised of a 
reporting unit that “represents a broiler complex comprising a group of farms in a 
common geographical area, which are served by a single feed mill.”) used for the study 
employed the service of starter and grower feeds containing anticoccidial drugs.  Some of 
those drugs have been available for over 50 years.  The drugs are classified as either an 
ionophore produced by fermentation or a chemical produced through chemical synthesis.  
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These two types of drugs are commonly used together in shuttle programs, or different 
drugs within each category are used intermittently (Chapman, 2001). 
Salinomycin (an ionophore) acts on coccidiosis by attacking the protozoan cell 
directly.  It increases the cation concentration inside the cell.  The cation concentration 
increase causes increased osmotic pressure leading to the lysing or inhibition of the 
protozoan cells (Bolder et al., 1999).   
The use of anticoccidal drugs has proven to be successful in the past.  Many 
studies have examined the performance of birds treated with anticoccidials when they 
were infected early in life (Chapman et al., 2004).  Chapman et al. (2004) investigated the 
performance of broilers given salinomycin and roxarsone and infected at older ages.  The 
study involved infecting the birds at 18 and 35 days of age.  The birds were also treated 
with either salinomycin, roxarsone, or salinomycin and roxarsone from 0 to 4, 0 to 5, or 0 
to 6 weeks.  The birds were infected with field isolates of E. acervulina, E. maxima, and 
E. tenella at 100,000; 30,000; and 50,000 oocysts per bird, respectively.  The study 
showed that the inclusion of anticoccidials decreases the number of oocysts that will be 
shed by the birds.  The differing lengths of the anticoccidial use in the study showed that 
using anticoccidials beyond 5 weeks will be advantageous to the birds to decrease oocyst 
numbers.  Longer use of anticoccidials decreased the feed:gain ratio but did not affect the 
body weights, mortality, or feed intake.  The birds infected later (35 days) and medicated 
until 5 or 6 weeks experienced decreased weight gain compared to the nonchallenged 
controls.  This report shows that the birds besides those medicated for 5 or 6 weeks and 
infected at 35 days had developed immunity.  Adequate time to develop immunity had 
not been achieved by those particular birds.  The study also showed that the use of 
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anticoccidial drugs is beneficial if used properly and under the correct circumstances, but 
if the withdrawal of the anticoccidial is required before slaughter, the birds may not be 
able to fight an infection with their own natural immunity.  The drug would have 
suppressed the bird’s ability to fight the infection on its own.  In fact, the author 
recommends that the producer should weigh the economic benefits associated with the 
improved feed conversion against the possible detrimental effects associated with the 
chance that the birds will not have developed proper immunity to fight late infection. 
Conway et al. (2002a and 2002b) further studied the effects of anticoccidial 
withdrawal.  More specifically, the study dealt with the organism E. tenella because 
earlier studies have shown that immunity to E. tenella is the slowest to develop out of the 
Eimeria species.  The first study (2002a) was performed to evaluate the withdrawal of 
diclazuril on days 28, 35, and 42 compared with salinomycin withdrawal on day 28.  The 
second study was performed to determine the level of immunity that diclazuril allowed at 
different withdrawal times and used the birds from the first study.   
In the first study, five treatment groups were used:  unmedicated (UNM); 
salinomycin + roxarsone in starter and grower (SAL 28); salinomycin + roxarsone in 
starter and diclazuril in grower until 28 days (DIC 28), 35 days (DIC 35) or 42 days (DIC 
42).  The birds were grown on litter naturally contaminated with E. acervulina, E. 
maxima, and E. tenella.  DIC treatments exhibited improved means for weight gain and 
feed conversion compared to SAL 28 and UNM treatments.  Feed conversion was better 
for the DIC 35 and DIC 42 compared to DIC 28.  UNM birds experienced the highest 
number of oocysts due to absence of coccidial treatment.  Both SAL and DIC treatment 
groups demonstrated efficacy by maintaining low oocyst counts.  By day 49, DIC 
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treatments had improved performance over UNM and SAL groups.  Adverse effects 
resulted from the withdrawal of both DIC and SAL on day 28.  Those two groups (DIC 
28 and SAL 28) suffered decreased performance compared to DIC 35 and DIC 42 
(Conway et al., 2002a).   
The birds used in the first experiment were used in the second experiment along 
with other birds raised in different conditions.  The treatment groups were carried over to 
this new study with two new groups:  nonexposed, nonchallenged (NENC) and 
nonexposed, challenged (NEC).  All birds, except the NENC birds were inoculated with 1 
X 105 E. tenella oocysts per bird on day 1 of the new study (day 56 of life).  They 
determined that birds that had diclazuril withdrawn on days 35 and 42 were highly 
susceptible to infection with E. tenella. UNM and SAL 28 treatments exhibited higher 
weight gain and lower lesion scores than the NEC and DIC treatments.  Conway et al. 
(2002b) determined that this was true because the UNM and SAL 28 treatments had 
developed immunity to E. tenella in the earlier study.  The DIC treatment group exhibited 
partial immunity to E. tenella because weight gain, feed conversion, and lesion scores 
improved compared to NEC treatment group.  The same level of immunity was not seen 
in DIC 35 or DIC 42.  These two studies reinforce the theory that late withdrawal of 
anticoccidials can lead to increased production costs if the birds experience a significant 
coccidiosis challenge after the withdrawal.   
Bird inability to cope with coccidiosis challenge after anticoccidial withdrawal is 
not the only concern involved with using the anticoccidial programs.  Another very 
important issue currently facing the industry is antimicrobial resistance. 
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ANTIMICROBIAL RESISTANCE 
A major concern associated with antimicrobial resistance in animal medicine is 
the development of resistant strains of microbes in animals that may eventually pass to 
humans.  Human medicine faces new challenges constantly.  Introducing resistant 
pathogens from animals on top of the resistant strains introduced by overuse of human 
antimicrobials could be very detrimental to human medicine.   
Currently, the resistant microbes involving humans exist mainly due to overuse of 
drugs in humans, but the concern associated with animal antimicrobials is rising 
(Bywater, 2005).  Another concern involving resistance is the possible failure to control 
disease in food animals.  If too many resistant strains infest food production, a 
catastrophic loss of animal products could result.  With so many people relying on 
animals for food, there is much at stake. 
With the ban of growth-promoting antibiotics taking place in Europe in 2006, the 
common practice of antimicrobial feed inclusion is being increasingly evaluated in the 
U.S.  This evaluation includes investigation into antimicrobial resistance.   
During the 1960s, the occurrences of a resistant strain of Salmonella typhimurium 
increased dramatically causing much concern.  The observation sparked the antimicrobial 
resistance exploration.  Since the first concern, many other resistant microorganisms have 
been discovered and studied.  The debate among the animal production community has 
inflated to determining the best course of action to inhibit the further development of 
antimicrobial resistant microorganisms.  The ban of the use of antimicrobials as growth-
promoters in Europe has had mixed results.  The removal of tetracycline as a growth-
promoter has not achieved the initial purpose.  The percentage of tetracycline resistant 
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strains of Salmonella spp. found in Europe remains slightly higher than that of the U.S. 
where it has not been banned.  The strains still exist in Europe because tetracycline is 
used to treat disease.  The treatment still allows for the development of the resistant 
strains (Bywater, 2005). 
The ban in Europe has also had adverse effects on the animal welfare and health.  
Clearly, the removal of proven growth-promoters, designed and used to increase the 
performance of animals and prevent disease outbreak, caused an increase in the 
consumption of antibiotics for therapeutic use to treat disease rather than prevent it 
(Bywater, 2005).  More information is needed to properly evaluate antimicrobial 
resistance, more specifically, resistance in pathogens causing coccidiosis. 
 Because coccidiosis is one of the most devastating diseases in the poultry 
industry, the routine use of anticoccidials has become almost a necessity as 99% of the 
poultry plants studied used an anticoccidial in both starter and grower feeds (Chapman, 
2001).  With the high incidence of use associated with anticoccidials, the likelihood of 
anticoccidial resistant microbes is very high.  Reports from the early 1950s indicated no 
incidents of resistance among field isolates for coccidiosis (Cucker et al., 1955).  Cuckler 
et al. (1955) went on to perform a study on resistance of field strains of coccidian and of 
laboratory strains of E. acervulina and E. tenella.  The study found that 43% of the 
allegedly resistant field strains were sensitive to various anticoccidials.  Nitrophenide 
resistance was encountered in 43% (13) of the field strains.  Nine of those 13 were also 
resistant to nitrofuazone and sulfaquinoxaline.  Nitrofurazone had the highest occurrence 
of resistance (57%).  Both E. acervulina and E. tenella developed tolerance for 
sulfaquinoxaline after many passages through the birds and recycling (Cucker et al., 
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1955).  This study shows how long the incidence of anticoccidial resistance has been 
present in the poultry industry. 
In 1974, Jeffers reported the drug resistance of E. tenella by obtaining field 
samples from over 1,000 poultry houses for 42 months (January 1970-June 1973).  The 
field strains were fed to poultry under treatment of Bonaid, Coban, Deccox, Coyden or 
Amprol Plus to evaluate the resistance of the field strains.  Any clinical signs of cecal 
coccidiosis exhibited by the birds were determined to be caused by drug-resistant strains 
of E. tenella. 
The study sampled 1,145 farms with 1,052 (91.9%) of them producing coccidian 
from the litter samples.  Out of the single anticoccidial programs investigated, birds on 
Nidrafur experienced the highest incidence of E. tenella infection (88.2%) with Zoamix 
having the second highest incidence (72.6%).  Jeffers does, however, state that the ability 
to distinguish between drug failure and resistance is limited.  The inability of Nidrafur, 
Coban, and Zoamix to control the detrimental effects of E. tenella is attributed to the 
possible limited anticoccidial activity of the drugs, not to resistance in E. tenella. Jeffers 
reported that Amprol Plus, Bonaid, Coyden, and Deccox use resulting in perpetuation of 
E. tenella is due to the development of resistance.  Observations in the study also 
supported the incidence of cross-resistance observed in chemically similar compounds.  
In the present study, Bonaid and Deccox were observed to cause cross-resistant strains of 
E. tenella. Overall Jeffers observed resistance in field isolates of E. tenella to 
anticoccidials commonly used at the time (Jeffers, 1974).     
While Jeffers (1974) used field strains of E. tenella that had already been exposed 
to various medications, McLoughlin et al. (1975) used a parental strain that had never 
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been exposed to anticoccidials.  The E. tenella was exposed to several passages through 
poultry medicated with amprolium, nicarbazin, Unistat and zoalene to mimic shuttle 
programs.  By the 40th and last passage, the coccidia had become resistant to all the 
anticoccidials except nicarbazin.  The study showed that shuttle programs are not capable 
of completely preventing the incidence of resistance.  In fact, this particular study 
produced a strain of coccidian that was resistant to three of the four anticoccidials to 
which it was exposed. 
McManus et al. (1968) studied field isolates of coccidia from commercial farms 
where buquinolate was unsuccessful in controlling coccidiosis.  Twelve strains were used 
from the commercial farms to be tested against other quinolate compounds.  The isolates 
were tested using amquinolate, buquinolate, M&B 15497 and methyl benzoquate with no 
response.  The field isolates were not susceptible to the four anticoccidials.  The field 
isolates exhibited a remarkable amount of quinolate resistance.  In fact, 3 of the strains 
were subjected to 10 times the recommended level of amquinolate and buquinolate 
without any anticoccidial effect.  Amquinolate became ineffective to laboratory strains of 
E. tenella, E. bruneti, and E. maxima after only four cycles of exposure.  This study 
demonstrated that resistance to amquionolate can develop quite rapidly leading to the 
question of its efficacy as an effective anticoccidial. 
As the aforementioned studies have demonstrated, anticoccidial resistant strains 
of Eimeria are found in the industry.  The studies have also shown that resistant strains 
have rendered some anticoccidials useless when used against them.  The resistant strains 
must be controlled.  The common use of anticoccidials has produced them, but they can 
be fought using strategies that support the prevalence of susceptible strains.  Previously, 
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using shuttle programs was thought to prevent the emergence of resistant strains by not 
allowing the protozoa sufficient exposure to one anticoccidial to develop immunity.  
McLoughlin et al. (1975) showed that resistance during a shuttle program is possible.  
With the emergence of resistant strains commonplace within the industry, how can the 
disease be controlled? 
One route of control exists with the introduction of drug sensitive strains of the 
coccidial organism into a production center.  Jeffers (1976) found that the introduction of 
a drug sensitive strain of E. tenella into a floor pen that was highly contaminated with a 
resistant strain led to the reduction of the resistant portion of the E. tenella population 
within the floor pen.  The resistant portion was reduced but not eliminated.  The fact that 
these resistant microbes were still present may suggest that using an anticoccidial to 
which the coccidia are resistant will promote the survival of the resistant strain.  This will 
transition the population to one that has a higher proportion of resistant strains.  A 
possible solution to anticoccidial resistance lies in the use of vaccination.   
 
COCCIDIOSIS VACCINES 
 The increasing concern with the routine use of antibiotics has elevated research 
involving vaccines.  The possibility of using the immune response in the chicken itself 
through vaccination has become a realistic alternative to anticoccidial compounds 
(Medarova et al., 2003). 
 Coccidiosis vaccines first emerged over 50 years ago.  CocciVac® was developed 
by Samuel Allen Edgar.  During the last 20 years of the 19th century, coccidiosis was 
studied intensely and steps were taken towards controlling the disease.  In 1925, it was 
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discovered that exposure to coccidiosis could cause immunity in chickens to the disease.  
This, and later studies laid the groundwork for the development of coccidiosis vaccines, 
but it would not occur until much later.  The scientists of this era concentrated on the 
chemotherapy aspect of coccidiosis control.  It was not until the 1940s that Edgar began 
contemplating the development of a coccidiosis vaccine.  W.T. Johnson began work 
involving immunity development to coccidiosis.  His untimely death in 1937 prevented 
his work to be finished.  Had he not died, he may have led the effort for control of 
coccidiosis through immunity development and later, vaccination (Williams, 2002a). 
 Johnson’s work was carried on by other scientists interested in using immunity to 
combat coccidiosis such as E.E. Tyzzer, E.R. Becker, R.L. Mayhew, M.M. Farr, E.M. 
Dickinson, and S.A. Edgar.  These scientists spent their time using dosages of Eimeria 
oocysts to elicit immunity in poultry.  Administration of the oocysts seemed to be the 
problem.  The oocysts were being killed before they could be used by the poultry.  Also, 
the doses of viable, virulent oocysts were not consistent from bird to bird.  Edgar began 
his first study in June 1942.  He confirmed that administering small doses of E. tenella 
oocysts would lead to the development of immunity without the consequence of mortality 
(Williams, 2002a). 
 Edgar realized early in his studies that uniform uptake of the viable vaccine must 
be achieved for success.  He also realized that birds remaining susceptible after 
vaccination needed chemotherapeutic intervention for protection.  He also realized that 
the administration of the vaccine should be done so at the earliest age possible to provide 
the chicks with early immunity.  The first vaccine (CocciVac®) was developed using only 
E. tenella oocysts and therefore criticized, but this work by Edgar laid the foundation for 
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the development of new and improved vaccines to provide today’s industry with the 
vaccines to fight the different Eimeria species causing coccidiosis (Williams, 2002a). 
 Currently, there are two types of coccidiosis vaccines available to the poultry 
industry:  non-attenuated and attenuated.  The non-attenuated vaccines are those that are 
made up of mixtures of wild type strains of Eimeria designed to provide the chicken with 
immunity without any pathogenic effects.  Attenuated vaccines contain mixtures of 
strains that were selected for reduced or no pathogenocity.  Coccidiosis vaccines are 
usually administered with the intention that the oocysts will be recycled in the litter and 
passed through the intestinal tract after the initial vaccination has occurred.  This 
necessary event provides the birds with the solid immunity available from proper 
vaccination procedure (Dalloul, 2004). 
 Vaccines can be administered by eye spray, spray cabinet, drinking water 
inclusion, feed inclusion, or edible gel.  Feed and water inclusion methods may need to 
be given during the first week of life, but the other methods can be used in the hatchery to 
achieve earlier immunity development.  Vaccines applied to drinking water must be 
injected into the drinking water system.  Typically, water is withheld for some time to 
make the birds thirsty.  The water-vaccine mixture is then administered allowing the birds 
to consume an adequate amount of vaccine.  The feed inclusion method can be done by 
simply spraying the vaccine evenly over the food.  The edible gel method involves giving 
the birds a brightly colored gel either in the crates in the hatchery or on flats in the barn 
shortly after placement.  The bright color appeals to the birds.  Careful watch must be 
employed to ensure that all birds are able to consume the gel.  The eye spray technique 
involves spraying the vaccine into the eyes of the birds to obtain absorption through the 
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nasolacrymal duct connecting the conjunctiva with the nasal cavity and oropharynx.   
Breeding companies prefer the use of spray cabinets.  It is believed to be administered 
evenly throughout the group of birds being vaccinated.  The method employs a cabinet to 
confine a group of birds.  The vaccine, mixed with a colored dye, is sprayed onto the 
birds.  The birds obtain the dose of vaccine by pecking and preening the colored vaccine 
(Chapman, 2000). 
 When using vaccines for control of coccidiosis, the species of coccidiosis used in 
the vaccine is of major concern.  The species of Eimeria vaccinated against varies 
between vaccines.  When considering broilers, all seven ubiquitous species do not need to 
be considered because E. brunetti and E. necatrix are very rarely encountered.  On the 
other hand, E. acervulina, E. maxima, and E. tenella are incorporated in all broiler 
vaccines (Williams, 2002b). 
 Vaccines to combat coccidiosis have now become readily available.  They have 
been employed in limited use since the 1950s.  The U.S. poultry industry has yet to 
readily accept the vaccines as a feasible alternative to anticoccidials despite their proven 
success in providing birds with protection against coccidiosis infection.  The vaccines 
have not been accepted because their use has been associated with poor weight gain and 
feed efficiency when compared to anticoccidial programs (Danforth, 1998).  
 Danforth (1998) performed several studies to determine efficacy of vaccination 
and vaccination-type programs to control coccidiosis.  His studies led to the conclusion 
that male and female birds are able to develop immunity against various coccidial species 
if vaccinated on the first day of life.  He determined that the method of delivery for the 
vaccine is very important.  The vaccine must be delivered to allow the uniform 
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distribution of a small number of parasites.  He also determined that the gel-delivery was 
the most successful in providing the chickens with the best protection from E. maxima.
His studies showed that using immunovariant Eimeria (immunological variants of 
Eimeria) in live vaccines may cause a drop in initial bird performance.  The broilers that 
experienced the initial performance decrease made up the losses by week 7.  At the time 
of slaughter, the vaccinated birds and medicated birds had achieved similar feed 
conversions and weight gain.  He also found that in floor pen trials, the use of a 
combination program involving vaccination on day 1 with drug-resistant Eimeria and use 
of an anticoccidial throughout the growth curve provided the broilers with protection 
almost completely.  The performance of the broilers was not reduced during the first 3 
weeks of life, but he found that in field trials, the birds that were vaccinated and given 
anticoccidials had reduced feed conversion values compared to the unvaccinated birds 
given anticoccidials.  While the results of his studies are not overly decisive, Danforth 
believes that interest in coccidiosis vaccines will only increase with time.   
 Mathis (1999) reported results of his floor pen study investigating coccidiosis 
vaccination effect on compensatory gain of broilers compared to unvaccinated broilers 
receiving salinomycin.  The study was performed on the broilers over 7 weeks beginning 
on the first day of life.  The vaccinated group was sprayed with Coccivac-B® at the 
hatchery.  The salinomycin group received salinomycin in the starter and grower feeds at 
a concentration of 66 ppm lasting for 5 weeks.  The vaccine-associated coccidiosis 
affected the performance of the vaccinated birds by 3 weeks of age.  The vaccinated birds 
experienced poor feed conversions and reduced weight gain compared to the salinomycin 
birds.  Week 3 data was the only data recorded throughout the study exhibiting 
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significant differences between the vaccinated and salinomycin groups.  The salinomycin 
treatment group was numerically superior to the vaccinated after week 3, but the slight 
differences between the two groups decreased with each successive week.  Mathis 
concludes that the vaccinated birds experienced a compensatory gain after facing a 
coccidial immune challenge. 
 A large-scale study was performed to determine the efficacy of Paracox® vaccine 
compared to nicarbazin-monensin shuttle program in broilers in Italy.  The study 
involved using three consecutive crops totaling 290,405 male and female broilers from 
winter 1997 until the summer of 1998.  The birds receiving anticoccidials were fed 
nicarbazin during the starter phase and monensin during both the grower and finisher 
phases.  The monensin was withdrawn from the diet 4 days prior to slaughter.  The 
vaccinated birds were vaccinated with Paracox® vaccine which was administered through 
the drinking water of the birds beginning at 5 days of age.  The trial had no subclinical or 
clinical signs of coccidiosis infection.  No lesions were observed throughout.  Two of the 
3 vaccinated flocks had oocysts detected in the litter beginning on day 14, and the third 
flock produced oocysts beginning on day 21.  The oocyst counts of the vaccinated flocks 
peaked at 27 days (22 days post vaccination).  No oocysts were detected after day 49 in 
the 3 vaccinated flocks.  The 3 anticoccidial flocks experienced detectable oocysts 
beginning on day 34 and continuing consistently until day 49 and reducing to 
undetectable level on day 56.  Total oocyst count was higher for the vaccinated flocks 
than it was for the anticoccidial flocks.  Up to day 21, no significant differences existed 
between mean body weights of the anticoccidial birds compared to the vaccinated birds.  
After day 21, the vaccinated birds were heavier than the anticoccidial birds.  They were 
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significantly so after from day 27 until trial conclusion.  The FCR for the vaccinated and 
anticoccidial birds were not significantly different.  At the processing plant, fewer 
vaccinated males were rejected than anticoccidial males, but there was no significant 
difference when considering the females.  This study demonstrates that the use of 
coccidiosis vaccines can produce comparable performance in broilers with anticoccidial 
shuttle programs.  One advantage of the vaccine programs over anticoccidials is the fact 
that vaccines do not require withdrawal before slaughter, and the vaccination may 
provide the broilers with added protection during the time just before slaughter (Williams 
et al., 2002).              
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EVALUATION OF COCCIVAC-B® AND SACOX 60® (SALINOMYCIN)  
FOR CONTROL OF 3 STRAINS OF EIMERIA IN BROILERS 
 
C.E. Brown1, R.G. Teeter1, A. Beker1, M. Singh1, C. Broussard2, S. Fitz-Coy2, J. Radu2
1Department of Animal Science, Oklahoma State University, Stillwater, Oklahoma  
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INTRODUCTION 
 
The commercial poultry industry has been very successful throughout the years.  
Even with the advancements that have arisen within the industry, companies continue to 
struggle with disease.  These diseases are caused by infectious organisms including 
viruses, protozoa, bacteria, etc.  Because the birds are housed in such ways that cause 
constant interaction, communicable diseases are spread rapidly throughout an entire 
housing facility.  The ability to control disease has become a necessity for success in the 
industry.   
 Coccidiosis is one of the most reported diseases in the industry (Williams, 2002b).  
Coccidiosis is a significant disease because of the rapid turnaround of the infection.  
Because of the short life cycle, an entire house can become infected in a very short period 
of time.  It costs the industry an estimated $800 million in losses.  This estimated cost 
considers the prevention medication, treatment medication, and losses due to mortality, 
inefficient feed utilization, temporary reduction of egg production, malabsorption, and 
impaired growth rate (Dalloul et al., 2005). 
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The term antimicrobial is a general term given to the very diverse group of 
biologically active compounds that act to combat infectious disease by attacking the 
harmful bacteria that might infect an animal or a human.  Historically, the coccidiosis 
problem has been minimized by the inclusion of antibiotics such as nicarbazin (Yoder et. 
al, 2006), salinomycin (Chapman et al., 2004), etc. in the bird’s diet.  Such drugs are only 
provided to the bird for a limited period of time and in concentrations so as to partially 
protect against coccidiosis with the bird eventually developing its own immunity.  The 
poultry industry refers to this as “slippage” (Chapman et al., 2004).   The deleterious 
consequence of coccidiosis challenge is dependent upon the time the chickens have their 
challenge with this being dependent upon the feed drugs and immunity level.  Some 
countries are considering the restriction of antibiotic application for the control of 
coccidiosis in an effort to protect humans from “super bugs”.  As of January 1, 2006, all 
growth-promotants such as virginiamycin have been prohibited from routine application 
in livestock by the European Union (Bywater, 2005).  If the restrictions for anticoccidial 
drugs are expanded to the U.S., the American poultry industry will face severe production 
consequences. 
 It is critical that new approaches such as vaccines be developed with efficacy to 
eliminate coccidiosis as an environmental stressor.  The development of vaccines to elicit 
immunity within the bird for the various coccidiosis lines offers the potential to eliminate 
the application of antibiotics in poultry diets for coccidiosis control (Medarova et. al, 
2003).   With vaccination, the birds start the immunization process on day 1 and would 
have maximal immunological protection by week 4 (Allen et. al, 1997). 
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Schering-Plough has developed a theory involving coccidiosis exposure and 
immunity called “Quadrants Performance”.  The quadrants are numbered 1-4.  The 
quadrants are divided by the performance and economic thresholds.  Increased oocyst 
numbers in a house above the performance threshold will severely impact the birds’ 
performance causing decreased weight gain and feed conversion.  The birds will show 
clinical signs of coccidiosis.  The economic threshold marks the point in terms of age 
after which experiencing a coccidiosis infection will dramatically impact performance to 
the point of devastating the economic achievement of the flock.  The quadrant 
designations can be seen in figures 45 and 46.  Schering-Plough has determined that 
experiencing a low coccidiosis challenge early in life will allow the birds to recover 
performance and develop immunity in the case of any future infection.  Their research 
has determined that the vaccination of the birds in the hatchery allows the birds to 
undergo a minimal immune challenge with low levels of oocysts in the litter (Figure 45) 
at an early age.  The birds then develop immunity thanks to the vaccine preventing any 
further harm due to coccidiosis later in the growth curve.  Their research (along with 
others) has shown that using ionophore programs (Figure 46) prevents the birds from 
undergoing an early, minimal challenge.  The birds are protected from coccidiosis until 
the period between ionophore withdrawal and slaughter.  The birds have crossed the 
performance threshold if they experience a coccidial infection during this time.  The 
challenge has come too late in life for the birds to recover from performance losses due to 
challenge.  Also, unless the housing facility is thoroughly cleaned specifically for 
coccidosis, the subsequent flocks will experience increased coccidosis challenge 
throughout the growth curve (Figure 47).          
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The purpose of this study is to contrast Coccivac-B® with Sacox 60® throughout 
the broiler’s growth curve.  It is important to examine efficacy throughout the growth 
curve as coccidiosis consequences are impacated by bird age and the bird will also 
eventually develop its own immunity.  Also, this research experiment seeks to establish 
that the Coccivac-B® vaccine is efficacious throughout the broiler’s growth curve to 
combat coccidiosis and is an alternative to the feed delivered antibiotics combating this 
problem.  Further, the study seeks to establish coccidiosis consequence as mediated by 
antibiotic slippage vs. Coccivac-B® vaccination throughout the growth curve by exposing 
broilers to typical field isolates on days 14, 21, 28, 35, and 42.   The vaccine offers the 
potential to reduce the undetermined rate of immunity development created by feeding 
low levels of antibiotics.  Immunity development by vaccination also has a production 
cost, and there may be times during the bird’s growth curve that the antibiotics will be 
superior.  It is important that the two methods be contrasted throughout the growth curve 
as coccidiosis consequences and therapeutic advantage is dependent upon bird age, 
challenge history, and immunity development at the time of coccidiosis exposure. 
 
MATERIALS AND METHODS 
 
TRIAL INITIATION  
Eleven hundred male Cobb x Cobb chicks were obtained from a commercial 
hatchery in Siloam Springs, AR.  Four hundred of the chicks were vaccinated with 
Coccivac-B®. The vaccine was administered as a spray vaccine for absorption through 
the mucosal membranes of the eyes and nasal cavity.  All the chicks were placed in boxes 
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of 100 for transport.  Two vehicles were used to transport the chicks.  The 400 vaccinated 
birds were transported in their own vehicle to ensure that the spray vaccine was not 
sloughed to the other 700 non-vaccinated chicks.  Upon arrival at Oklahoma State 
University, the unvaccinated chicks were randomly placed into floor pens.  To ensure 
biosecurity, the control group receiving no treatment for coccidiosis prevention was 
assigned first in a separate facility.  At least one bird was taken from every box of 100 
unvaccinated birds for each pen.  The birds to receive 60g/ton Sacox 60® (salinomycin) 
feed were placed after the control birds using the same technique and the remaining 
unvaccinated birds.  The vaccinated birds were placed last to ensure that no vaccine 
residue was passed to the other birds.  Thirteen birds were placed in each of 72 total pens 
with 24 pens per treatment group (vaccinated:  Coccivac-B®; salinomycin:  60g/ton 
Sacox 60®; and control:  no treatment) after a group weight for each pen was recorded.  
All birds were fed a starter ration containing 22.1% CP and 3,053 Kcal/kg ME until day 
21.  The salinomycin birds were fed this ration with an addition of 60g/ton Sacox 60®
until day 35 to provide them with coccidiosis protection.  All the birds were taught how 
to drink water from nipples and given feed and water for ad lib consumption throughout 
the trial.      
The birds were wing banded on day 5 and individual weights were recorded on 
day 7.  Also, one bird from each pen was removed and humanely sacrificed to obtain day 
7 body composition using the DEXA x-ray densitometer.  The birds were monitored 
multiple times per day to ensure that proper conditions were utilized to promote bird 
health.  Throughout the study, disposable plastic boots and foot baths containing 
ammonia were utilized by each worker before entering either housing facility to minimize 
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the risk of contaminating either facility with coccidiosis.  Different coveralls were also 
used for each house to aid with biosecurity.   
 
CHALLENGE PERIODS 
On day 14 challenge period 1 was initiated.  Birds were randomly and blindly 
selected using only wing band records.  Mortality was taken into consideration when 
selecting birds for removal.  Birds were removed so that the number of birds per pen was 
reduced to nine.  All birds were then individually weighed and predetermined birds 
removed.  The feed left in the feeders was weighed before adding more feed so that feed 
consumption could be determined.  Of all the birds removed, 168 were moved to the 
metabolic chambers.  A total of 56 birds were taken from each of the three treatment 
groups.  Exactly one half of the birds from each treatment group (28) were predetermined 
to be either challenged or unchallenged.  The unchallenged birds were given an oral dose 
of 1 ml sterile water.  The challenged birds were given an oral dose of 1 ml coccidiosis 
solution containing oocysts of Eimeria maxima, Eimeria acervulina, and Eimeria tenella 
at concentrations of 20,000; 50,000; and 30,000 oocysts per bird, respectively. The 
chambers were randomly assigned with one of the six treatments (vaccinated no 
challenge:  V-; vaccinated challenged:  V+; control no challenge:  C-; control challenged:  
C+; salinomycin no challenge:  S-; salinomycin challenged:  S+).  Two birds were placed 
in each of the smaller chambers (termed “broiler” chambers), and four were placed in the 
larger chambers (termed “turkey” chambers).  The chamber methodology and 
characteristics have been described by Weirnusz and Teeter (1993).  In this particular 
study, the grating on the bottom of the chambers was covered with large sheets of heavy 
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duty paper to help the birds adapt quicker to the new environment in the chambers.  A 
small amount of feed was also placed on the paper to aid with accommodation to the 
chambers.  Oxygen consumption and carbon dioxide were recorded hourly for six days to 
determine heat production using the equation provided by Brouwer (1965).  Feed and 
water were still available while the birds were in chambers with feed being added to 
feeders as needed to maintain ad lib consumption.   
On day 20, the birds in the metabolic chambers were removed, body weight 
recorded, and the feed left in the feeder was weighed as feed weighback to determine 
feed consumption per chamber.  Next, the birds were humanely sacrificed using cervical 
dislocation.  The birds were surgically eviscerated by a coccidiosis expert from Schering-
Plough to perform lesion scoring on each bird.  The GI tract was examined at three 
critical points for gross lesion scoring.  The upper small intestine, mid small intestine, 
and the ceca were all surgically opened and scored for lesions associated with coccidiosis 
infection.  The scores ranged from 0 (no lesions) to 4 (severe lesions and hemorrhaging).  
While scoring, scrapings were taken from each of the previously mentioned areas and 
smeared on microscope slides to obtain microscopic lesion scores based on the number 
and type of oocysts.  The microscopic lesion scores were also given values ranging from 
0 to 4 based on the number of oocysts seen per view.  After all the birds were removed 
from chambers, the chambers were thoroughly cleaned with ammonia to kill any 
remaining oocysts and paper was replaced in the bottom to prepare for the next challenge 
period. 
The procedure outlined for day 14 was repeated on days 21 (challenge 2), 28 
(challenge 3), 35 (challenge 4), and 42 (challenge 5) with the only differences being the 
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number of birds used each challenge period and the dosages of oocysts used for the 
challenge.  On day 21, the number of birds per floor pen was reduced to 7.  On days 28, 
35, and 42, the number of birds in the floor pens was reduced to four, two, and zero, 
respectively.  Forty-eight birds were taken from each treatment group to be moved to the 
chambers for a total of 144 birds moving to the metabolic chambers on days 21 and 28.  
On day 35, 36 birds from each treatment group were moved to the chambers.  On day 42, 
the number decreased to 28.  The birds from each treatment were evenly divided between 
challenged and unchallenged for each challenge period.  For challenges 2 and 3, the 
broiler chambers housed two birds, and the turkey chambers housed three.  For challenge 
4, the broiler chambers held 1 bird and the turkey held 3.  During the fifth challenge 
period, the broiler chambers held 1 bird and the turkey held 2.  The dosage for the 
challenged birds on day 21 was 30,000; 60,000; and 37,000 oocysts per bird for E. 
maxima, E. acervulina, and E. tenella, respectively.  On day 28 the challenge dosages for 
E. maxima, E. acervulina, and E. tenella were as follows:  30,000; 80,000; and 40,000 
oocysts per bird, respectively.  On day 35 the challenge dosages for E. maxima, E. 
acervulina, and E. tenella were 40,000; 90,000; and 50,000 oocysts per bird, respectively; 
and on day 42 the dosages were 55,000; 105,000; and 50,000 oocysts per bird, 
respectively.  The oocysts were increased throughout to coincide with increasing body 
weights of the birds.  Also the dosages were increased to mimic the increase of oocysts 
that would occur in a typical house without proper control.  As birds are exposed to the 
oocysts, they will be ingested and recycled to litter.  The numbers would increase rapidly, 
so the oocysts per bird dosages were increased to mimic the increasing number 
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experienced in an infected house.  On days 27, 34, 41, and 48 (six days post challenge), 
the procedure for day 20 was repeated exactly as described.     
 
FEED 
All birds were reared on a typical broiler diet containing 22.1% CP and 3,053 
Kcal/kg ME during the starter phase determined to be from initiation until day 21 for this 
particular study.  This starter diet was provided as mash with the salinomycin birds 
receiving an addition of 60g/ton Sacox 60® to their feed.   
 Beginning on day 21, all groups were fed the grower feed containing 19.8% CP 
and 3,131 Kcal/kg ME and fed as pellet feed.  The salinomycin birds continued to receive 
60g/ton Sacox 60® through day 35 when they were fed the same feed as the other 
treatment groups until the trial conclusion on day 48.   
 Both feeds (starter and grower) were prepared as one large basal ration.  After the 
basal ration was prepared, the required amount for the vaccinated and control birds was 
bagged, and labeled.  The remaining feed was mixed with a premix containing the 
required amount to achieve 60g/ton Sacox 60® activity.  After sufficient mixing, the feed 
was bagged and labeled. 
 
VARIABLES 
Weekly body weights were taken on all birds in the floor pens.  This coordinated 
with the removal of birds from floor pens to be moved to metabolic chambers.  The 
weights were taken on individual birds using wing bands to clearly identify the bird.  
Feed added to each floor pen was also recorded.  On the days that birds were weighed 
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and removed from the floor pens (days 14, 21, 28, 35, and 42), the feed left in each pen 
was weighed and recorded as feed “weighback” so that feed consumption for each pen 
could be determined on a weekly basis and for the correct number of birds.  The birds 
that were moved to the metabolic chambers for challenges were weighed before going 
into the chambers recorded as the weekly weight for the particular bird.  Six days post 
challenge, the birds were weighed as they were removed from the chambers.  The feed 
added to each chamber was recorded, and the feed removed after the challenge period 
was weighed as feed “weighback” to determine feed consumption while in the chamber.  
While the birds were in the chambers, oxygen consumption and carbon dioxide 
production were measured at least once per hour to later determine heat.  Birds were 
eviscerated by an expert from Schering-Plough Animal Health who was held blind to bird 
identity.  The birds were examined by the expert as described above to determine lesion 
scores for the intestinal.  The birds were frozen until DEXA analysis to determine body 
composition.  From the DEXA scan body protein, fat, water, and ash were determined.  
Also, percent protein, fat, water, and ash were determined by dividing the grams of each 
divided by body weight.  The protein, fat, water, and ash gains were determined using the 
scan data of unchallenged birds to develop regression equations.  The regression 
equations used live weight.  The initial weights of the birds entering the chambers were 
used with the equations to determine initial composition.  The initial composition data 
was subtracted from the DEXA data to determine the gains of protein, fat, water, and ash. 
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LIGHTING SCHEDULE 
The birds were placed on a lighting schedule throughout the trial.  To allow for 
maximum environment adaptability, the birds were given 24 hours of light from day 1 
through day 7.  From day 8 through day 14, the birds were placed on 18 hours of light 
and 6 hours dark.  From day 15 to day 35, the birds were given 14 hours of light and 10 
hours of dark.  From day 36 until the conclusion of the trial on day 48, the birds were 
given 22 hours of light with 2 hours of dark.   
STATISTICAL ANALYSIS 
 Data was analyzed using statistical analysis software (SAS). The trial was 
arranged using a 2 x 3 factorial arrangement.  The trial used 2 groups for Challenge (+ or 
-) and 3 for treatment (Control, Salinomycin, or Vaccinated).  The 2 x 3 factorial 
arranged the treatments into 6 groups:  C+, C-, S+, S-, V+, and V-.  Treatments were 
separated using the Least square means procedure when a significant F statistic was 
detected.  All comparisons of data were considered significant when P<0.05.  
Performance data was analyzed using each respiratory chamber as an experimental unit.  
Composition data was analyzed using each individual bird as an experimental unit. 
 At the experiment initiation, the social interaction of the birds on the same 
treatment was deemed more important than the treatment housing due to possible vaccine 
particle migration to one of the other two treatment groups in the parent population.  
Consequently, it is not possible to statistically contrast population performance (df = 0) 
due to spatial housing differences between treatments.  It was thereby decided that small 
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live weight differences between treatment groups being allocated to the metabolic 
chambers would be used as a covariant to evaluate the metabolic chamber data. 
 
RESULTS 
 
FLOOR PENS 
 It cannot be determined whether the differences seen in the floor pen data 
(“backgrounding period”) were resultant of the treatment groups or the physical 
placement of the birds in separate areas.  In this study, bird location effects were 
confounded with treatment and/or not possible to statistically represent.  Regardless, the 
results for the “backgrounding period” are shown in Table 2.   
CHALLENGE PERIODS 
 Being challenged with the coccidial mixture depressed feed consumption 
throughout the trial.  The birds in the + group did not consume as much feed as the – 
group during each challenge period.  V+ birds exhibited significantly higher feed 
consumption to C+ birds after day 20 (P<0.01).  V+ birds consumed significantly less 
feed than the S+ birds (P<0.01) and similar feed compared to the C+ group (P=0.29) on 
day 20.  The V+ birds ate more feed than S+ birds on days 41 (P<0.01) and 48 (P<0.01).  
On the other days, V+ and S+ had similar feed consumption (P>0.14).  V- birds 
consumed significantly less feed than the C- birds (P<0.01) on day 20 and not different 
feed when compared to both S- and C- birds after day 20 (Table 3). 
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Challenge impacted the body weight, live weight gain, Average Daily Gain 
(ADG), and feed efficiency.  The challenged (+) birds had depressed values for all those 
performance criteria throughout the trial compared with the unchallenged (-) birds.  V+ 
birds were superior to the C+ birds in terms of body weight, live weight gain, ADG, and 
feed efficiency (P<0.02).  The C+ birds were also inferior for body weight, live weight 
gain, ADG, and feed efficiency compared with the S+ birds (P<0.01) throughout except 
day 48 (P<0.21) where the two groups were similar for those variables.  The V+ birds 
had significantly lower live weights, less live weight gain, and lower ADG than the S+ 
birds (P<0.02) until day 34 when they were not significantly different (P=0.10).  On days 
41 and 48, the V+ birds were significantly heavier and had significantly more live weight 
gain and ADG than the S+ birds (P<0.01).  The V+ birds also had better feed efficiency 
than the S+ birds after day 34.  V+ birds were inferior to S+ in terms of feed efficiency 
on days 20 (P<0.01) and 34 (P<0.01).  On day 27, the two groups were similar (P=0.13).  
Only on day 20 did any differences exist between the – groups for body weight, live 
weight gain, and ADG.  On day 20, the V- birds were significantly lighter, had lower 
ADG, and less body weight gain than the C- birds (P=0.02), but they were equal to the S- 
birds.  C- birds exhibited increased feed efficiency to the V- birds on day 27 (P<0.01) 
with all other comparisons for feed efficiency of – birds exhibiting no differences (Table 
3). 
 Challenge was very important for the development of gross lesion scores (upper 
small intestine, middle small intestine, and ceca).  As expected, the challenged (+) birds 
had dramatically increased gross lesion scores throughout the trial compared with the 
unchallenged (-) birds.  V+ birds exhibited fewer upper and middle SI lesions throughout 
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versus C+ birds (P<0.03) and after day 34 versus S+ birds (P<0.01).  S+ birds exhibited 
fewer upper and middle SI lesions than C+ birds (P<0.01) through day 34.  On day 41, 
the S+ birds had similar upper and middle SI lesion scores to C+ birds (P<0.15).  S+ 
birds exhibited indifferent upper SI lesion scores and fewer middle lesion scores on day 
48 to the C+ birds (P=0.17 and P=0.04, respectively).  The S+ group had fewer upper SI 
and similar middle SI lesions compared with the V+ group on day 20 (P<0.01 and 
P=0.08, respectively).  V- birds exhibited similar amounts of middle SI lesions 
throughout versus C- birds (P>0.05) and S- birds (P>0.07).  V- birds exhibited fewer 
upper SI lesions on day 20 versus C- birds and S- birds (P<0.01) with all other days being 
statistically similar (Table 4).  
V+ birds exhibited fewer cecal lesions after day 20 versus C+ birds (P<0.01) and 
after day 34 versus S+ birds (P<0.01).  The S+ birds had fewer cecal lesions than V+ 
birds on days 20 (P=0.01) and 27 (P=0.01).  The two groups were statistically not 
different for cecal lesion scores on day 34 (P=0.55).  The S+ birds had fewer cecal 
lesions than C+ birds (P<0.01) throughout except on day 41 where they are not different 
(P=0.36).  V- birds exhibited similar amounts of cecal lesions throughout versus C- birds 
and S- birds (Table 4). 
 All – groups experienced similar amounts of E. acervulina, E. maxima, and E. 
tenella lesions throughout the trial.  No significant differences were observed amongst 
these three treatments for E. acervulina, E. maxima, and E. tenella lesion scores.  The 
microscopic lesion scores had a significant reliance on challenge throughout the study.  
The + groups experienced higher lesion scores throughout compared with the – groups 
with only one exception.  On day 27, the + and – groups did not experience significantly 
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different lesion scores for E. acervulina. The + birds did not experience a significant 
challenge from the E. acervulina on that day as reflected in Table 5.  
V+ birds exhibited fewer E. acervulina, E. maxima, and E. tenella lesions 
throughout versus C+ (P<0.02).  Throughout the trial, V+ birds exhibited fewer E. 
maxima lesions compared to the S+ birds (P<0.01).  Lesions scores for E. acervulina of
V+ birds and S+ birds were not different through day 34.  The S+ group had a lower E. 
tenella lesion score than the V+ group on day 27 (P<0.01).  S+ birds and V+ birds had 
similar E. tenella lesion scores on days 20 (P=0.24) and 34 (P=0.06).  The V+ birds had 
lower E. acervulina and E. tenella scores than S+ birds on days 41 (P<0.01) and 48 
(P<0.01).  S+ birds had lower E. acervulina and E. tenella lesion scores throughout 
versus C+ birds (P<0.03) except on day 41 (P<0.17) when they were not different.  S+ 
birds had similar amounts of E. maxima lesions compared to C+ on days 27 (P=0.50) and 
41 (P=0.52).  The S+ birds had fewer E. maxima lesions versus the C+ group (P<0.02) on 
all other days (Table 5). 
 No differences in total challenge period heat production were observed within the 
– treatment groups.  V-, S-, and C- birds were not different throughout the trial in terms 
of total challenge period heat production.  The V+, S+, and C+ birds were also similar 
throughout the trial with only one exception.  The C+ birds had a decreased total 
challenge period heat production on day 41 (P=0.05) compared to the S+ birds (Table 6). 
 Birds in the – treatment groups maintained similar retained energy (RE) values 
throughout the trial except that V- birds had a lower RE on day 20 compared to the S- 
(P=0.03) and C- birds (P=0.01).  V+ birds had higher RE than C+ birds throughout the 
trial (P<0.02).  The V+ birds had lower RE than S+ on days 20 (P<0.01) and 27 (P=0.04).  
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V+ had higher RE than S+ on days 41 (P<0.01) and 48 (P<0.01).  The V+ and S+ groups 
were not different on day 34 (P=0.42).  S+ birds had similar RE compared to C+ on day 
48 (P=0.76).  The C+ birds had lower REs on days 20 (P<0.01), 27 (P<0.01), 34 
(P<0.01), and 41 (P<0.01) compared to S+ birds.  Challenge significantly affected 
retained energy.  Throughout the trial, the challenged birds (+) had significantly lower 
RE compared with the unchallenged (-) birds (Table 6). 
 Retained energy efficiency (REE) was determined by dividing the RE by 
metabolizable energy consumption during the challenge period.  Challenge impacted 
REE on all days but 48.  Before day 48, the + birds experienced a decreased REE 
compared with the – group.  Birds in the – treatment groups had similar REE except on 
days 27 where the V- birds had decreased REE compared to both C- (P=0.01) and S- 
(P=0.01) birds.  The C+ treatment group had an indifferent REE to S+ on day 48 
(P=0.65).  On all other days, C+ REE was lower than REE of S+ (P<0.02).  The C+ 
group had similar REE to V+ on day 48 (P=0.19).  On all the other days, the V+ group 
had higher REE than C+ (P<0.01).  V+ birds exhibited higher REE compared to S+ birds 
on day 41 (P<0.01).  Because the V+ birds performed better than the S+ birds after day 
34 in most categories, the V+ birds would be expected to have a higher REE than S+ on 
day 48, but they did not.  The two groups were statistically similar (P=0.05), but V+ birds 
were numerically superior.  The two groups were not different on days 27 (P=0.25) and 
34 (P=0.07).  The S+ birds were superior to V+ birds on day 20 (P<0.01) in terms of REE 
(Table 6). 
 The results for body composition content are very similar between the different 
constituents (protein, fat, water, and ash).  The challenged birds had less protein, fat, 
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water, and ash throughout the trial due to their reduced body weights versus the 
unchallenged birds.  The trends seen in each are very similar to each other when 
comparing the same ages and treatments.  Birds in – treatment groups had similar protein, 
water, and ash content after day 27 and similar fat content after day 20.  The C- birds had 
more protein, fat, water, and ash content than the V- birds on day 20 (P=0.01) and more 
protein on day 27 (P=0.04).  S- and V- birds were not different throughout the entire trial 
for fat and protein content.  S- and V- birds were not different throughout the entire trial 
concerning water and ash content except on day 27 where S- birds had higher ash and 
water content (P=0.05).  S- birds had less fat, water, ash, and protein content than C- 
birds on day 20 (P=0.03) and they were not different on day 27 (P>0.89).  V+ birds had 
less protein, fat, water, and ash content than S+ birds on day 20 (P<0.01) and more on 
days 41 and 48 (P<0.01).  The V+ and S+ groups had similar protein, fat, water, and ash 
content on days 27 (P<0.05) and 34 (P<0.25).  The V+ birds had more protein, water, 
ash, and fat content throughout versus the C+ birds.  The S+ birds had similar fat, ash, 
water, and protein content to C+ birds on day 48 (P<0.77).  On all other days, the S+ 
birds had more protein, fat, water, and ash than the C+ birds (Table 7). 
 The protein, fat, water, and ash gains were severely impacted by challenge.  The + 
birds had significantly less protein, fat, water, and ash gain compared to the – birds 
throughout the trial (P<0.01).  Birds in + groups experienced the same trends for protein 
and fat gain during the challenge periods.  On days 20 and 27, the V+, S+, and C+ birds 
were all significantly different.  The S+ birds experienced the most protein and fat gain 
on these days with the V+ birds second and C+ birds last.  On day 34, the S+ birds and 
V+ birds had similar protein (P=0.43) and fat (P=0.42) gain.  On days 41 and 48, the C+ 
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and S+ birds are similar for both protein and fat gain.  They both had significantly 
reduced protein and fat gain compared to V+ birds.  On days 20 (P=0.01) and 27 
(P=0.02), the V- birds had reduced protein and fat gain compared with C- birds.  After 
day 27, all the – treatment groups had the same fat and protein gain.  The V- birds also 
exhibited similar protein gain to the S- birds on day 20 (P=0.05), but reduced fat gain 
(P=0.02).  The V- birds also had a lower fat and protein gain than S- (P<0.05) birds on 
day 27.  C- birds were similar to the S- birds throughout the trial for protein and fat gain 
(Table 8).   
 The + treatment groups experienced similar patterns for water and ash gain.  The 
V+ treatment group had increased water and ash gain after day 34 compared with S+ 
birds.  They had the same water (P=0.47) and ash (P=0.42) gain as the S+ birds on day 
34.  The S+ birds had higher water and ash gain compared with V+ prior to day 34.  The 
V+ birds had increased water and ash gain versus the C+ birds throughout the trial.  The 
C+ birds and the S+ had similar water (P=0.77) and ash (P=0.73) gain on day 48.  On day 
20, the V- birds exhibited similar water and ash gain to the S- birds (P<0.10).  On day 27, 
the V- birds achieved the same water gain as the S- birds (P=0.05).  The V- birds had 
reduced ash and water gain compared to the C- birds on days 20 (P=0.01) and 27 
(P=0.02).  After day 27, the water and ash gain of V-, C- and S- were not different.  The 
water and ash gain of S- is indifferent to that of C- throughout the trial (Table 8). 
 Protein percentage was highly dependent on challenge except on days 34 and 41.  
On those two days, the protein percentage of the + group was similar to that of the – 
group.  On days 20 and 27, the + birds experienced decreased protein percentage 
compared with the – birds, but on day 48, the + birds experienced increased protein 
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percentage.  The – treatments had similar protein percentage on days 20, 41, and 48.  V- 
had the same percentage of body weight as protein as C- and S- throughout the trial.  S- 
had a higher protein percentage of body weight than C- on days 27 (P=0.02) and 34 
(P=0.02).  Those two treatments were similar on all other days.  The V+ treatment group 
experienced higher protein percent than the C+ birds on day 27 (P=0.01).  On all other 
days C+ and V+ had the same protein percent.  S+ birds had a higher protein percent than 
the V+ birds on day 48 (P=0.04).  These two treatments were not different on all other 
days.  The S+ birds had similar protein percentage compared with C+ birds except on day 
27 where the S+ birds achieved a higher protein percent than the C+ birds (0.03; Table 
9).  
 The challenged birds experienced higher fat percents throughout versus the 
unchallenged birds.  The fat percentage of – treatments were not different throughout the 
trial except on day 34.  On day 34, the S- had an increased fat percent compared to the C- 
birds (P=0.04).  The V- birds had the same fat percent as both the S- (P=0.31) and C- 
(P=0.28) birds on day 34.  V+ birds and S+ birds had similar fat percentages on days 27 
(P=0.52) and 34 (P=0.98).  On day 20, S+ had a higher fat percentage compared to the 
V+ (P=0.03) and C+ (P<0.01) birds.  On days 34 and 41, C+ birds had lower fat percents 
than both V+ and S+ birds.  V+ birds had increased fat percent compared with S+ birds 
on days 41 (P=0.01) and 48 (P=0.01) and compared to C+ birds throughout.  S+ birds had 
higher fat percent than the C+ birds on days 20 (P<0.01), 27 (P<0.01), 34 (P<0.01), and 
41 (P=0.01).  The S+ group had the same fat percent as the C+ group (P=0.84) on day 48 
(Table 9).      
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The – birds had decreased water percent on days 20, 41, and 48 compared with 
the + birds.  On days 27 and 34, the two groups were similar.  V+ birds had an increased 
water percentage versus S+ on day 20 (P=0.05).  V+ had a decreased water percentage 
compared to C+ on days 41(P=0.01) and 48 (P=0.04).  They were similar to C+ in terms 
of water percent on days 20 (P=0.89), 27 (P=0.67), and 34 (P=0.05).  The V+ birds had 
similar water percent compared to S+ birds on days 27 (P=0.19) and 34 (P=0.18).  They 
had decreased water percent compared with S+ birds on days 41 (P=0.01) and 48 
(P=0.01).  The – treatments were not different on days 20, 41, and 48 for water percent.  
On day 27, the V- birds had similar water percentages compared to both C- (P=0.10) and 
S- (P=0.33) birds.  The S- birds had increased water percentage compared with C- birds 
(P=0.01).  On day 34, the S- birds reached similar water percent with both V- (P=0.91) 
and C- (P=0.06) groups.  The V- birds had increased water percent compared with the C- 
treatment group (P=0.04) on day 34 (Table 9).    
 Ash percentage was highly dependent on challenge on days 20, 27, and 48.  On 
days 20 and 27, the + birds experienced decreased ash percentage compared with the – 
birds, but on day 48, the + birds experienced increased ash percentage.  On days 34 and 
41, the ash percentage of the + group was similar to that of the – group.  The ash 
percentage of the – birds is not different on days 20, 41, and 48.  The V- birds had similar 
ash percentage with the S- and C- birds on day 27 and 34.  The S- birds had increased ash 
percents on day 27 (P= 0.02) and 34 (P=0.03) compared to C- birds.  The S+ and V+ 
birds had similar ash percents throughout the trial.  The C+, V+ and S+ birds all had 
similar ash percentages on days 34, 41 and 48.  The S+ birds had higher ash percents than 
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the C+ birds on days 20 (P=0.01) and 27 (P=0.03).  The V+ birds had increased ash 
percentage on days 20 (P=0.04) and 27 (P=0.01) compared to C+ birds (Table 9). 
 Heat production was calculated using composition data (HPc).  It was calculated 
using the following equation:  HPc= Metabolizable Energy consumed- Retained Energy.  
The retained energy was calculated using the protein and fat gain from the composition of 
the birds.  Both protein gain and fat gain were multiplied by their respective energy 
values of 5.65 kcal/gram and 9.3 kcal/gram.  Those values were added to quantify the 
energy retained as tissue in the birds.  The challenge group was evaluated against the 
unchallenged birds.  The HPc of the challenged birds was higher than that of the 
unchallenged birds except on days 27 and 48 when they were statistically indifferent.  C+ 
birds had an indifferent HPc compared to the V+ birds on day 20 (P=0.06).  The C+ 
group had increased HPc compared to V+ group on all other days.  The C+ birds 
exhibited higher HPc than the S+ birds on all days except day 48 where the two groups 
were not different (P=0.86).  The V+ birds had a lower HPc compared to the S+ birds on 
days 41 (P=0.01) and 48 (P=0.01).  All other days, the two were similar.  The V- birds 
had an increased HPc compared to both the S- (P=0.03) and C- (P=0.03) birds on day 27.  
On all other days, the – treatment groups were similar to each other (Table 6).   
 Heat production from composition (HPc) was further investigated by dividing it 
by the metabolic body weight giving the heat production per unit metabolic body weight 
(HPMB).  The metabolic body weight was calculated by raising the body weight to the 
0.75 power.  The + group and the – group were analyzed to determine the general effects 
of a coccidial challenge.  The challenged birds experienced an increased HPMB 
throughout the trial compared with the unchallenged birds indicative of the coccidial 
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challenge they were experiencing.  The C+ birds had a higher HPMB compared to the V+ 
birds throughout the trial.  The S+ and C+ groups had an indifferent HPMB on day 48 
(P=0.89).  On all other days, C+ had a higher HPMB.  The C+ birds had a higher HPMB 
on all days compared to the V+ birds.  V+ birds exhibited a higher HPMB on day 20 
compared to the S+ birds (P=0.0366).  These two treatment groups were not different on 
days 27 (P=0.76) and 34 (P=0.06).  The V+ birds exhibited less HPMB on days 41 
(P=0.01) and 48 (P=0.02) compared to the S+ birds.  The V- birds exhibited an elevated 
HPMB compared to both the C- (P=0.02) and S- (P=0.03) birds on day 27.  All other 
comparisons between the – groups, on all other days yielded no differences (Table 10).  
 Metabolizable Energy (ME) consumption was calculated by multiplying the feed 
consumption by the ME content of the diet.  The ME of the birds was highly dependent 
upon challenge.  The + group consumed significantly less ME than the – group 
throughout the trial.  The C+ birds and V+ birds exhibited similar ME consumption on 
day 20 (P=0.10).  The V+ birds consumed more ME than the C+ birds throughout the rest 
of the trial.  The S+ birds displayed an increased ME consumption compared to the C+ 
birds on days 20 (P<0.01), 27 (P<0.01), 34 (P<0.01), and 41 (P=0.01).  They had similar 
ME consumption on day 48 (P=0.90).  The V+ birds consumed an similar amount of ME 
versus S+ birds on days 27 (P=0.06) and 34 (P=0.45).  The V+ birds consumed less ME 
than S+ birds on day 20 (P<0.01) and more on days 41 (P<0.01) and 48 (P<0.01).  The 
only differences existing for ME consumption of – treatment groups were found on day 
20.  The V- birds exhibited decreased ME consumption compared to the C- (P<0.01) and 
S- (P<0.01) birds.  No other differences existed for – treatment groups for ME 
consumption throughout the trial (Table 10).         
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HPc was divided by ME consumption to determine the heat production per 
kilocalorie of ME consumed (HPMEc) with lower values defining better performance.  
The challenged birds experienced a higher HPMEc than the unchallenged birds 
throughout the trial.  The V- birds exhibited a higher value on day 27 compared to the C- 
(P=0.01) and S- (P=0.03) birds.  All other comparisons between – treatment groups 
showed no differences.  S+ exhibited a decreased HPMEc compared to the V+ birds on 
day 20 (P<0.01).  These two groups exhibited similar HPMEc values on days 27 (P=0.35) 
and 34 (P=0.13).  The V+ birds had lower HPMEc values on days 41 (P<0.01) and 48 
(P=0.01).  The C+ birds exhibited increased HPMEc versus S+ on all days but 48.  On 
day 48, the C+ and S+ groups were not different in terms of HPMEc (P=0.93).  The V+ 
birds exhibited lower HPMEc compared with C+ throughout the trial (Table 10). 
 Metabolizable energy consumption depression associated with challenge (MEcr) 
was determined by subtracting the ME consumption of the unchallenged birds (-) birds 
from the ME consumption of challenged birds (+); therefore, the results presented 
compare the treatment groups at different ages without challenge consideration.  A lower 
value indicates better performance and protection during challenge.  The V birds had a 
decreased value compared to C birds on days 34 (P=0.01), 41 (P<0.01), and 48 (P=0.01).  
The V birds were not different to the C birds on days 20 (P=0.27) and 27 (P=0.11).  The 
S birds exhibited decreased MEcr on days 27 (P=0.01) and 34 (P=0.01) compared with C 
birds.  The C group and S group were similar on days 20 (P=0.13), 41 (P=0.39), and 48 
(P=0.09).  S and V groups exhibited similar MEcr on days 20 (P=0.68), 27 (P=0.38), and 
34 (P=0.45).  The V birds had a decreased MEcr on days 41 (P=0.01) and 48 (P=0.02) 
compared to the S birds (Table 11).   
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Maintenance energy elevation due to challenge (MC) was determined by the 
following equation:  (ME consumption – accretion energy) – body weight0.75 X 110 X 6 
for challenged birds - (ME consumption – accretion energy) – body weight0.75 X 110 X 6 
for unchallenged birds.  The accretion energy is the energy from protein and fat gain.  As 
for MEcr, the results compare treatment groups at different ages without challenge 
consideration.  The C birds had a higher maintenance energy cost due to challenge (MC) 
than the S birds on days 27 (P=0.01), 34 (P<0.01), and 41 (P=0.01).  The S and C groups 
exhibited similar MC values on days 20 (P=0.16) and 48 (P=0.12).  The V birds had 
decreased MC compared with S birds on days 41 (P<0.01) and 48 (P=0.01).  On all other 
days, these two groups were not different for MC.  The V birds exhibited depressed MC 
compared with C birds on days 27 (P=0.01), 34 (P<0.01), and 41 (P<0.01).  On days 20 
(P=0.40) and 48 (P=0.29), the C and V groups were not different (Table 11).   
 Total caloric cost of challenge (TCC) is determined by the addition of MEcr and 
MC to quantify the total energy cost of a coccidiosis challenge.  S birds had decreased 
TCC compared to C birds on days 27 (P=0.01), 34 (P<0.01), and 41 (P=0.01).  On days 
20 (P=0.06) and 48 (P=0.94), the C and S groups were not different.  The S birds had 
increased TCC values compared to V birds on days 41 (P<0.01) and 48 (P=0.01).  The V 
birds exhibited similar TCC to C birds (P=0.21) on day 20.  On all other days, the C birds 
were similar to the V birds (Table 11).       
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DISCUSSION 
 
CHALLENGE PERIODS 
 The results suggest that the V birds (V+ and V-) experienced an early immune 
challenge due to the vaccination.  The early performance of the V birds was slightly 
decreased compared with the S birds.  The performance of the V- birds was somewhat 
decreased compared with the other – treatments, but the V- birds caught up to the other – 
treatments at the end of the trial (Odd-numbered figures 1-9 and 23-43).  This fact alone 
is not enough to determine the presence of a challenge, but coupled with the elevated 
lesion scores early in the trial supports an early challenge due to vaccination.  The 
challenged and the unchallenged V birds both had elevated lesion scores (gross and 
microscopic) early in the trial.  Figures 11 through 22 emphasize this presence of an early 
challenge in the vaccinated birds.  The odd-numbered plots especially support the early 
challenge because those represent the different lesion scores of the – birds.  In every case 
involving the unchallenged birds, the V birds have at least slightly elevated lesion scores 
(gross and microscopic) in the early part of the trial above both of the other groups (C 
and S).  Earlier studies have supported the fact that vaccination causes an early immune 
challenge in the chickens to elicit immunity allowing them to better cope with the 
introduction of the microorganisms later in life.  The results reported from this study 
support the formation of immunity.  The V+ birds performed poorer than or similar to the 
S+ birds through day 34 (Tables 3, 4, and 5).  After the withdrawal of the Sacox 60® on 
day 35, the S+ birds were no longer able to cope with a coccidiosis challenge.  The S 
birds did not develop immunity during the trial because the Sacox 60® protected them 
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from most exposure to coccidiosis.  The natural immunity of the chickens was not 
utilized by the S birds to fight coccidiosis, and it had very detrimental consequences seen 
through the heavy losses occurring in the S+ birds’ performance after day 34 compared 
with the V+ birds (Tables 3, 4, 5 and even-numbered Figures).  Conway et al. (2002a and 
2002b) and Chapman et al. (2004) had similar conclusions concerning the withdrawal of 
anticoccidials.  The birds that were medicated with anticoccidials performed poorly when 
challenged with coccidiosis after withdrawal of the anticoccidial. 
 The performance results here are similar to those of Mathis (1999).  The 
vaccinated birds in his study experienced poor performance compared to birds given 
salinomycin in the beginning of the trial.  After week 3, the vaccinated birds became 
similar to the salinomycin birds.  We experienced similar results in that the vaccinated 
birds in this study also had reduced performance at the start of trial, but they became 
similar to, and in our study, surpassed the salinomycin birds.    
 Performance of – birds is related to the microscopic and gross lesion scores.  The 
V- birds experience increased lesion scores during the first challenge period.  They also 
experienced decreased performance in terms of live weight, body weight gain, and feed 
efficiency.  The poor performance was most likely caused by the challenge involved in 
giving the live vaccine clearly visible by the increased lesion scores.  The C- and S- birds 
experienced virtually no lesion scores throughout and their performance results showed 
no coccidiosis challenge, as it should not have.  During the final two challenge periods, 
the V+ birds had lower, almost nonexistent, microscopic and gross lesion scores.  The S+ 
birds had higher incidences of lesions which were reflected in their decreased 
performances during the last two challenge periods.  The C+ birds had increased lesion 
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scores throughout and they also had poor performance throughout.  The results for the 
lesion scores correlate well with performance.  The lesion scores tended to be higher 
when birds were also performing poorly.  Clearly, the increased lesion scores resulting 
from coccidiosis had detrimental effects on bird performance.  The only exception to this 
is that the S+ birds had comparable lesion scores to the V+ and C+ birds during the early 
stages of the trial, but they had better performance.  It appears that the salinomycin 
prevented the coccidiosis from stunting the birds’ performance, but it did not prevent the 
occurrence of intestinal lesions.             
 The total challenge period heat production calculated from the gas data (HPg) is 
very interesting.  HPg may be expected to change based on the challenge involved with 
the birds.  Increasing the stress of the bird through challenge is typically cause for an 
increase in heat production.  In this study, heat production from gas was shown to remain 
fairly static.  The challenged birds were similar to the unchallenged birds throughout the 
trial.  There were small differences found in some treatment x challenge interaction 
instances, but as figures 23 and 24 show, the HPg of the different treatment groups 
remains similar.  It is possible that a deeper issue is involved.  In this case, the heat 
production was mediated by immunological response or nutrient utilization.  A further 
investigation into heat production was performed using the composition data. 
 Retained energy is correlated with the performance data.  In the beginning of the 
trial, the V+ birds have a much lower RE compared with the S+ birds (Figure 26).  As the 
birds grow and recover, they are able to utilize more of the feed energy as accrued protein 
and fat.  The S+ birds begin to lose the ability to retain energy as they become susceptible 
to the coccidiosis challenge.  This is also reflected in the retained energy efficiency data.  
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Figure 28 shows the dramatic shift in S+ REE as the birds have the Sacox 60® withdrawn 
from the feed and are unable to remain efficient when they experience a coccidiosis 
challenge during the withdrawal period.  Figure 27 shows how the V- birds have reduced 
efficiency in the beginning of the experiment because they are facing a challenge from 
the vaccine and the oocyst mixture.  By the end of the experiment, the vaccine has 
provided them with immunity allowing them to become more closely efficient with the S- 
and C- groups.   
 The even-numbered figures from 30 through 36 illustrate the increase of body 
substrates seen in the V+ birds over time as they develop immunity.  The figures here 
illustrate that the amount of each constituent will increase as the body weights increase.  
If the total body has a higher mass, the composition making up that body will also 
increase in mass.  The comparison of figure 4 with any of these clearly illustrates the 
correlation of the composition masses with the live mass of the bird. 
 Figures 38 and 40 illustrate the effects of the withdrawal of Sacox 60®. Figure 38 
shows an increase in the protein percentage of the S+ birds.  In figure 40, we can see the 
increase in the fat percentage of the V+ birds.  Typical growth curves show that after 
maturity, the birds should begin to decrease protein accretion and increase fat accretion.  
After growth is completed, the buildup of fat begins.  These two figures illustrate that the 
V+ birds have grown to the point of accruing fat.  The S+ birds are suffering the ill 
effects of the post-withdrawal coccidiosis challenges.  The birds are not gaining sufficient 
weight for their bodies to be accruing a higher percentage of fat tissue compared with 
lean tissue.  Leanness is a common sign of disease and general lack of health.   
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Figure 42 explains the poor efficiency of the S+ birds described earlier.  The birds 
are displaying a much higher percentage of water in their body than the other groups.  
Increasing the water percentage in the body does nothing for the bird energetically 
speaking.  The increase of water in the body will reduce the energetic efficiency of the 
bird because the bird gets no energetic use out of water.  The increased water on days 41 
and 48 is correlated with the S+ birds experiencing a significant coccidiosis challenge.  
The birds are either unable to accrue protein and fat with efficiency at this point, or they 
experienced increased water percentage due to edema caused by the coccidiosis infection.  
Either way, it is clear that the inability of the birds to defend against coccidiosis after 
salinomycin withdrawal caused the birds to have higher percent water.   
 The heat production values obtained from the composition data (HPc) indicate 
that the S+ birds were protected from the coccidiosis challenge until day 41.  After the 
withdrawal of the salinomycin, those birds were unable to cope adequately with a 
challenge.  They experienced increased heat production after the withdrawal on day 35 
compared with the V+ birds.  They experience HPc that was similar to the C+ birds on 
day 48.  That fact implies that the S+ birds had no advantage over the C+ birds in terms 
of HPc.  The V+ birds had a numerically elevated HPc compared with the S+ birds 
indicating that they were experiencing a slightly increased challenge over S+ birds.  The 
V+ birds exhibited the same HPc as the S+ birds until day 41 where they had decreased 
HPc indicating that they had developed and maintained immunity.  They were able to 
cope with the challenge as indicated by the fact that their HPc was not elevated 
significantly above the three – groups.  The challenge they received caused no increase to 
HPc compared with unchallenged birds.   
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Heat production per metabolic body weight (HPMB) was investigated to .  The 
results for HPMB support the Schering-Plough Quadrants of Performance theory.  The 
V- birds had elevated HPMB on day 20 compared to the C- and S- birds.  This indicates 
that the V- birds were most likely experiencing an immune challenge from the 
vaccination.  This challenge aided the birds in building up immunity to coccidiosis, as 
seen with the reduction of the V+ birds’ HPMB at the end of the trial.  During the final 2 
challenge periods, the V+ birds had HPMBs that were lower than the C+ and S+ birds, 
and statistically similar to the unchallenged treatment groups.  Again, this is indicative of 
the protection that the V+ birds are given by the early immune challenge due to 
vaccination.  It is clear with these results that the S+ birds experienced negative 
consequences after the salinomycin withdrawal on day 35.  They had increased HPMB 
compared to the V+ birds.  The C+ birds experienced detrimental effects of coccidiosis 
challenge throughout the trial.  They had significantly higher HPMB values compared to 
V+ birds throughout, indicating that they were undergoing significant immune challenge 
due to the lack of any protection against coccidiosis.  Figure 52 shows the progression of 
the HPMB through the growth curve of the challenged birds.  The C+ birds are producing 
more heat throughout, and the S+ birds catch up to them at the end of the trial.  Figure 51 
shows the elevation of the V- birds due to vaccine challenge early in the trial, but they 
become similar at the end of the trial.   
 The heat production per kilocalorie of ME consumed (HPMEc) was determined 
by dividing the HPc by MEc.  This value is a simple way to quantify the percentage of 
MEc that was lost as heat, in other words, the percentage of MEc that was wasted.  The 
results are very conclusive.  The S+ birds have the lowest value in the beginning showing 
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that they are able to utilize the MEc more efficiently.  They are protected against the 
challenge better than the V+ birds during the first challenge.  There was less heat 
production for the S+ birds at that time most likely due to the lack of immune challenge 
from the coccidiosis dosage.  The C+ group had increased HPMEc because they were not 
protected.  More of the ME they consumed was lost as heat due to the largely detrimental 
effects of the coccidial challenge.  The V+ birds were also numerically elevated 
compared to the S+ birds during the first chalenge because they were experiencing an 
immune challenge from the coccidiosis challenge and vaccine challenge.  The S+ birds 
had elevated HPMEc compared to the V+ birds on days 41 and 48.  The S+ birds were 
unable to retain efficiency during this time because of the withdrawal of the salinomycin.  
The V+ birds were able to utilize the MEc for accretion instead of wasting the energy for 
the immune challenge.  The V+ birds were protected throughout.  The unchallenged birds 
were had similar HPMEc throughout with the exception of day 27.  The V- birds were 
elevated on this day compared to the S- and C- birds.  They were likely still dealing with 
an immune challenge from the vaccination. 
 The amount of MEc depression associated with a coccidiosis challenge (MEcr) 
was quantified.  The value was determined by subtracting the MEc of the challenged 
birds from the MEc of the unchallenged birds.  This allowed us to determine the extra 
amount of MEc that was consumed by the unchallenged birds compared to the challenged 
birds.  Lower valued indicated better performance of challenged birds.  When a group 
had a lower value, the group was able to cope with the challenge better because they 
continued to eat similar to if they had not been challenged.  The V birds had decreased 
MEcr after day 34 compared to S birds illustrating that the vaccine was able to protect 
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longer in the growth curve after the salinomycin had been withdrawn.  The S birds had 
lower MEcr before day 41 compared with the C group, but on days 41 and 48, the two 
were not different.  This indicates that the S birds were no more protected than the C 
birds after salinomycin withdrawal.  The V+ birds were able to consume more ME 
relative to the V- birds than the S+ birds were able to relative to the S- birds.  The 
coccidial challenge impacted the MEc of the S birds more than it did the V birds after the 
salinomycin withdrawal.  The C birds’ MEc was significantly impacted by coccidial 
challenge throughout. 
 Maintenance energy elevation due to challenge (MC) was determined using the 
following equation:  (ME consumption – accretion energy) – body weight0.75 X 110 X 6 
(maintenance energy) for challenged birds – (ME consumption – accretion energy) – 
body weight0.75 X 110 X 6 (maintenance energy) for unchallenged birds.  The accretion 
energy is found by adding the energy values for protein and fat gain:  accretion energy = 
(protein gain X 5.65 kcal/gram)/Kp + (fat gain X 9.3 kcal/gram)/Kf.  The Kp and Kf 
values are standards commonly used.  Maintenance energy is determined using metabolic 
body weight (body weight0.75) and a value derived from previous studies performed at the 
OSU poultry farm defining the maintenance energy requirement per day (110).  The 6 
used in the equation is the number of days considered, in this case 6 days for each 
challenge period.  The increase in maintenance energy because of challenge will come 
from energy typically used for accretion.  The V birds displayed reduced MC compared 
to the S birds after salinomycin withdrawal.  The increase in immune challenge of S birds 
pulls energy from the accretion portion and uses it to maintain the bird.  The S birds fall 
in performance because they are not able to cope with the challenge, but the V birds have 
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developed immunity thanks to vaccination.  They are able to deal with the challenge and 
do not require as much of the total energy for maintenance; therefore, they are able to use 
more energy for accretion.  The C birds had to use more of their energy for maintenance 
throughout most of the trial compared to the S and V birds.  They were not protected at 
all, and the effects were obvious.   
 The total energy cost of coccidial challenge is quantified by adding the MC and 
MEcr.  The V birds developed less of an energy loss due to challenge at the end of the 
trial.  On days 41 and 48, they have the least cost of challenge.  The V+ birds were able 
to consume more ME relative to V- birds, and they were able to utilize a similar amount 
of that energy for accretion instead of maintenance.  The S+ birds were able to consume 
and utilize energy early in the trial, but they failed after withdrawal.  The C+ birds were 
not able to consume and utilize energy throughout the trial.    
 The predicted ME consumption was calculated using the derived value for 
maintenance energy requirement per day per metabolic body weight and the protein and 
fat energy values.  The equation to calculate the predicted ME consumption is as follows:  
110 X body weight0.75 X 6 days + (protein gain X 5.65)/Kp + (fat gain X 9.3)/Kf.  The 
predicted ME consumption was plotted against the actual ME consumption of the birds in 
Figures 48, 49, and 50 for the Control, Salinomycin, and Vaccinated birds, respectively.  
Every plot shows the challenged vs. the unchallenged birds.  Figure 48 illustrates the 
impact of the challenge on the control birds receiving no protection.  The unchallenged 
birds’ ME consumption follows the predicted value almost perfectly, but the challenged 
birds fall below the unchallenged birds.  They cannot keep up with the unchallenged.  
They are not accruing the protein and fat that they should be accruing.  The salinomycin 
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birds (Figure 49) follow the proper trend much better than the control birds.  It is clear in 
the plot that some of the S+ birds have fallen below where they should, but the S birds 
are clearly performing better than the control birds.  The vaccinated birds follow the 
correct path like the S birds.  They have a more even distribution of unchallenged and 
challenged birds throughout the ME consumption.  The challenged birds performing poor 
on the S plot are most likely the ones that were challenged after withdrawal.  They are 
performing poorly due to immune challenge.  
 
CONCLUSION 
 
It is clear from the data that the challenged groups did undergo immune 
challenges in the form of coccidiosis infection.  Salinomycin is an effective means of 
controlling coccidiosis caused by E. acervulina, E. maxima, and E. tenella, especially in 
the early stages of the broiler’s growth curve.  Salinomycin can significantly improve 
performance and reduce lesion scores associated with coccidiosis infection.  After 
withdrawal, the birds previously given salinomycin will be severely impacted by a 
significant coccidiosis infection.  The birds are not able to develop any natural immunity 
against coccidiosis and will be defenseless when the salinomycin is withdrawn.  The cost 
of challenge is outlined previously as the total cost of challenge (TCC).  It is clear that the 
vaccinated birds did not lose as much energy as reduced ME consumption or as increased 
maintenance energy due to coccidial challenge compared to the salinomycin birds after 
withdrawal of salinomycin on day 35.  The data reported herein supports Schering-
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Plough’s “Quadrants of Performance” theory.  Vaccination with Coccivac-B® gives the 
bird the means to develop immunity against coccidiosis caused by E. acervulina, E. 
maxima, and E. tenella. The vaccine causes initial immune challenge possibly retarding 
performance, but the vaccinated birds have the ability to rebound and improve 
performance before reaching market weight.  The vaccinated birds were better equipped 
to deal with a coccidial challenge later in life. 
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TABLE 1:  Composition of diets used for broilers throughout experiment 
Age interval (days) and Treatments1
0 to 21 21 to 35  35 to 48 
Ingredient, % S V and C S V and C S, V, and C 
Corn 58.3 58.3 64.529 64.529 64.529 
Soybean meal (48 % CP) 34.56 34.56 28.21 28.21 28.21 
Soybean oil 2.83 2.83 2.93 2.93 2.93 
Dicalcium phosphate                        1.87 1.87 1.98 1.98 1.98 
Limestone                             1.18 1.18 0.92 0.92 0.92 
NaCl                                     0.35 0.35 0.29 0.29 0.29 
Roche Vitamin Premix2 0.2 0.2 0.2 0.2 0.2 
NaHCO3 0.24 0.24 0.32 0.32 0.32 
DL-Methionine                      0.21 0.21 0.22 0.22 0.22 
Huber trace mineral3 0.09 0.09 0.09 0.09 0.09 
Lysine HCl 0.06 0.06 0.157 0.157 0.157 
Selenium 600 premix 0.04 0.04 0.04 0.04 0.04 
Threonine                    0.02 0.02 0.05 0.05 0.05 
Ethoxyquin                               0.01 0.01 0.012 0.012 0.012 
Choline Chloride                     0.01 0.01 0 0 0 
Copper Sulfate 0 0 0.002 0.002 0.002 
L-Arginine                    0.03 0.03 0.05 0.05 0.05 
Sacox-60® (Salinomycin) 0.05 0.00 0.05 0.00 0.00 
Stafac-20® (Virginiamycin) 0.05 0.05 0.05 0.05 0.05 
Calculated Analysis       
Men (kcal/kg) 3053 3053 3,131 3,131 3,131 
CP, % 22.1 22.1 19.8 19.8 19.8 
Arg 1.38 1.38 1.30 1.30 1.30 
Lys 1.12 1.12 1.14 1.14 1.14 
Met 0.51 0.51 0.52 0.52 0.52 
TSAA 0.83 0.83 0.88 0.88 0.88 
Ca 0.90 0.90 0.80 0.80 0.80 
P, available 0.44 0.44 0.40 0.40 0.40 
1Treatments:  C = Control; V = Vaccinated; S = Salinomycin.   
2Supplied per kilogram of diet: vitamin A, 10,141 IU (retinyl acetate); cholecalciferol, 3,086 IU; vitamin E, 
23.92 IU (dl--tocopheryl acetate); menadione, 2.87 mg; thiamine, 2.20 mg; riboflavin, 7.72 mg; niacin, 
60.30 mg; d-pantothenic acid, 12.46 mg; pyridoxine, 3.75 mg; vitamin B12, 0.017 mg; folic acid, 1.066 mg; 
d-biotin, 0.127 mg.  
3Supplied per kilogram of diet: Ca,160 mg; Zn, 100 mg; Mn, 120 mg; Fe,75 mg; Cu, 10 mg; I, 2.5 mg. 
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TABLE 2: Feed Consumption (FC), Body Weight (BW), Body Weight Gain (BW Gain), and Feed 
Efficiency (FE) of Male Broilers During Floor Pen Period 
Treatment FC (g) BW (g) BW Gain (g) FE (g/g) 
Age 7 days     
C 160 190 145 0.91 
S 158 187 142 0.90 
V 166 195 150 0.91 
Age 14 days     
C 415 492 299 0.72 
S 395 485 296 0.75 
V 410 501 305 0.75 
Age 21 days     
C 606 936 442 0.73 
S 607 923 440 0.72 
V 584 914 411 0.70 
Age 28 days     
C 993 1569 635 0.64 
S 966 1529 603 0.63 
V 930 1492 571 0.61 
Age 35 days     
C 1188 2252 681 0.57 
S 1189 2239 703 0.59 
V 1135 2145 667 0.59 
Age 42 days     
C 1370 3071 780 0.57 
S 1368 3034 772 0.57 
V 1332 2888 718 0.54 
C = Control; S = Salinomycin; V = Vaccinated; g=gram; FC=Weekly feed consumption per bird; FE=BW 
Gain (g)/FC (g) 
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TABLE 3:  Feed Consumption (FC), Body Weight (BW), Average Daily Gain (ADG), Body Weight 
Gain (BW Gain), and Feed Efficiency (FE) of Male Broilers During Challenge Periods 
Treatment Challenge FC (g) BW (g) ADG (g/d) BW Gain (g) FE (g/g) 
Age 20 days       
C + 335a 598a 18a 108a 0.32a
S + 395b 712b 37b 217b 0.54b
V + 348a 645c 25c 150c 0.43c
C - 444c 796d 51d 302d 0.68d
S - 430cd 777de 48de 282de 0.65d
V - 408bd 752e 44e 258e 0.63d
Trt 0.0004 0.0004 0.0003 0.0003 0.0003 
Chall <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0002 <0.0001 <0.0001 <0.0001 <0.0001 
Age 27 days       
C + 598a 1093a 29a 169a 0.28a
S + 710b 1321b 68b 397b 0.56bc
V + 677b 1275c 60c 351c 0.52bc 
C - 714b 1330b 69b 406b 0.57b
S - 714b 1313bc 66bc 389bc 0.55bc 
V - 712b 1291bc 63bc 368bc 0.52c
Trt 0.0042 <0.0001 <0.0001 <0.0001 <0.0001 
Chall 0.0002 <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0024 <0.0001 <0.0001 <0.0001 <0.0001 
Age 34 days       
C + 720a 1713a 27a 161a 0.23a
S + 876b 2059bc 87bc 507bc 0.58b
V + 888bc 2023b 80c 471bd 0.53c
C - 919bc 2088c 92b 536c 0.58b
S - 924c 2080c 90b 528c 0.57b
V - 924bc 2063bc 87bc 511cd 0.55bc 
Trt <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Age 41 days       
C + 752a 2261a 8a 45a 0.06a
S + 841b 2425b 36b 209b 0.24b
V + 991c 2673c 78c 457c 0.45c
C - 1058cd 2763cd 93cd 547cd 0.51c
S - 1065cd 2763cd 93cd 546cd 0.51c
V - 1093d 2771d 95d 555d 0.51c
Trt <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0016 <0.0001 <0.0001 <0.0001 <0.0001 
Age 48 days       
C + 801a 2930a -16a -83a -0.11a
S + 840a 3032a 4a 19a 0.00a
V + 1144b 3473b 87b 459b 0.40b
C - 1079b 3414b 76b 400b 0.35b
S - 1046b 3413b 76b 399b 0.36b
V - 1095b 3415b 76b 402b 0.36b
<0.0001 0.0004 0.0004 0.0004 0.0007 
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt 
Chall 
Trt*Chall 0.0002 <0.0001 <0.0001 <0.0001 0.0002 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; g=gram; FE=BW Gain 
(g)/FC (g); Trt=Treatment (C, S, V); Chall=Challenge (+, -) 
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TABLE 4:  Gross Lesion Scores for Male Broilers During Challenge Periods 
Treatment Challenge Upper Mid Ceca 
Age 20 days     
C + 2.24a 1.64a 2.78a
S + 0.42b 0.75b 2.05b
V + 1.72c 1.14b 2.56a
C - -0.03d -0.02c 0.02c
S - 0.02d 0.01c 0.03c
V - 1.05e 0.43bc 0.37c
Trt <0.0001 0.0115 0.0027 
Chall <0.0001 <.0001 <0.0001 P value 
Trt*Chall <0.0001 0.0043 0.0151 
Age 27 days     
C + 0.41a 0.47a 2.34a
S + 0.01b -0.02b 0.62b
V + 0.00b -0.01b 1.27c
C - 0.00b 0.01b 0.00d
S - 0.00b 0.01b 0.00d
V - 0.01b -0.02b 0.00d
Trt 0.0006 <0.0001 <0.0001 
Chall 0.0023 0.0005 <0.0001 P value 
Trt*Chall 0.0002 <0.0001 <0.0001 
Age 34 days     
C + 0.55a 1.16a 2.79a
S + 0.00b 0.12b 1.19b
V + 0.00b 0.00b 1.32b
C - 0.00b -0.01b 0.01c
S - 0.00b 0.00b 0.01c
V - 0.00b 0.04b -0.06c
Trt 0.0005 <0.0001 <0.0001 
Chall 0.0023 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 41 days     
C + 1.94a 2.13a 2.95a
S + 1.96a 2.43a 2.75a
V + -0.01b 0.03b 0.87b
C - 0.01b 0.00b 0.02c
S - 0.01b 0.00b 0.03c
V - -0.01b 0.00b -0.02c
Trt <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 48 days     
C + 2.04a 2.43a 2.56a
S + 1.76b 1.93b 1.28b
V + 0.05c 0.03c 0.24c
C - -0.02c -0.01c 0.00c
S - -0.02c -0.02c 0.00c
V - 0.03c 0.02c -0.01c
<0.0001 0.0004 0.0004 
<0.0001 <0.0001 <0.0001 P value 
Trt 
Chall 
Trt*Chall <0.0001 <0.0001 <0.0001 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; Upper=Upper Small 
Intestine Lesion Score; Mid=Middle Small Intestine Lesion Score; Ceca=Cecal Lesion Score; 
Trt=Treatment (C, S, V); Chall=Challenge (+, -) 
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TABLE 5:  Microscopic Lesion Scores for Male Broilers During Challenge Periods 
Treatment Challenge E. acervulina E. maxima E. tenella 
Age 20 days     
C + 2.88a 2.51a 3.65a
S + 1.43b 1.98b 2.83b
V + 1.72b 1.24c 3.10b
C - 0.06c 0.06d 0.13c
S - -0.01c -0.01d 0.07c
V - 0.92d 0.22d 0.50c
Trt <0.0001 0.0075 0.0229 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 0.0002 0.0138 
Age 27 days     
C + 0.38a 2.09a 3.67a
S + -0.01b 1.94a 1.00b
V + 0.03b 0.11b 2.12c
C - 0.00b 0.00b 0.00d
S - 0.00b 0.00b 0.06d
V - 0.04b 0.06b 0.31d
Trt 0.0625 <0.0001 <0.0001 
Chall 0.0810 <0.0001 <0.0001 P value 
Trt*Chall 0.0277 <0.0001 <0.0001 
Age 34 days     
C + 0.96a 2.67a 3.81a
S + 0.05b 2.06b 1.40b
V + 0.00b 0.00c 0.83b
C - 0.00b 0.00c 0.00c
S - 0.00b 0.00c 0.00c
V - -0.02b 0.00c 0.16c
Trt <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 41 days     
C + 3.17a 2.95a 3.54a
S + 3.43a 3.15a 3.80a
V + 0.00b 0.00b 0.36b
C - 0.00b 0.03b -0.01b
S - 0.00b 0.03b 0.04b
V - 0.00b -0.03b 0.31b
Trt <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 48 days     
C + 2.39a 2.95a 3.30a
S + 2.05b 2.40b 1.69b
V + 0.16c 0.13c 0.04c
C - 0.05c 0.06c 0.08c
S - 0.00c 0.01c 0.03c
V - 0.01c -0.01c 0.01c
<0.0001 <0.0001 0.0004 
<0.0001 <0.0001 <0.0001 P value 
Trt 
Chall 
Trt*Chall <0.0001 <0.0001 <0.0001 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; E. acervulina= 
Eimeria acervulina lesion score; E. maxima= Eimeria maxima lesion score;  E. tenella= Eimeria tenella 
lesion score; Trt=Treatment (C, S, V); Chall=Challenge (+, -) 
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TABLE 6:  Heat Production Composition (HPc), Heat Production from Gas (HPg), Retained 
Energy (RE), and Retained Energy Efficiency (REE) for Male Broilers During Challenge Periods 
Treatment Challenge HPc (kcal) HPg (kcal) RE (kcal) REE 
Age 20 days      
C + 743a 619ab 289a 0.27a
S + 658bc 694ab 542b 0.45b
V + 694ab 590b 362c 0.34c
C - 620c 714a 708d 0.52d
S - 644bc 705a 664d 0.51d
V - 634c 641ab 598b 0.48bd
Trt 0.2610 0.5467 <0.0001 <0.0001 
Chall <0.0001 0.0924 <0.0001 <0.0001 P value 
Trt*Chall 0.0139 0.0869 <0.0001 <0.0001 
Age 27 days      
1C + 1448a 941a 406a 0.23a
3S + 1272bc 1088a 946b 0.42bc 
5V + 1283bc 1045a 843c 0.40b
2C - 1249c 1045a 1004b 0.45c
4S - 1250c 1028a 984b 0.44c
6V - 1365ab 1016a 879bc 0.39b
Trt 0.0517 0.7501 <0.0001 <0.0001 
Chall 0.1259 0.9483 <0.0001 <0.0001 P value 
Trt*Chall 0.0007 0.5813 <0.0001 <0.0001 
Age 34 days      
C + 1863a 1289a 410a 0.19a
S + 1407b 1423a 1328bc 0.49bc
V + 1529b 1403a 1272c 0.45c
C - 1474b 1408a 1425b 0.50b
S - 1422b 1367a 1445b 0.50b
V - 1506b 1351a 1386bc 0.47bc 
Trt <0.0001 0.9113 <0.0001 <0.0001 
Chall 0.0003 0.9697 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 0.5836 <0.0001 <0.0001 
Age 41 days      
C + 2140a 1336a 145a 0.14a
S + 1926b 1660b 654b 0.25b
V + 1625c 1600ab 1364c 0.43c
C - 1599c 1706b 1606d 0.51d
S - 1667c 1572ab 1621d 0.50cd 
V - 1667c 1530ab 1675d 0.49cd 
Trt 0.0032 0.7065 <0.0001 0.0008 
Chall <0.0001 0.4231 <0.0001 <0.0001 P value 
Trt*Chall 0.0001 0.0764 <0.0001 <0.0001 
Age 48 days      
C + 2629a 1647a -75a 0.29ab 
S + 2593a 1840a -173a 0.24a
V + 2041b 1862a 1437b 0.42ab 
C - 2143b 1781a 1219b 0.36ab 
S - 2125b 1686a 1082b 0.40ab 
V - 2115b 1726a 1344b 0.42b
Trt 0.0134 0.8538 0.0012 0.1833 
Chall 0.1365 0.6458 <.0001 0.1299 P value 
Trt*Chall 0.1222 0.4751 0.0087 0.3773 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; HPc= Metobolizable 
energy (ME) consumed –RE; RE=Protein gain*5.65 + Fat gain*9.3; REE= RE/ME consumed; 
Trt=Treatment (C, S, V); Chall=Challenge (+, -) kcal=kilocalorie 
83
TABLE 7:  Protein, Fat, Water, and Ash Content of Male Broilers After Challenge Periods
Treatment Challenge Protein (g) Fat (g) Water (g) Ash (g) 
Age 20 days      
C + 101a 60a 420a 15a
S + 119b 74b 489b 17b
V + 107c 66c 445c 16b
C - 134d 86d 543d 20c
S - 129e 82e 524e 19d
V - 126e 80e 514e 18d
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 27 days      
C + 187a 129a 734a 28a
S + 226bc 164bc 870bc 33bc 
V + 219c 158c 847c 32c
C - 230b 167b 881b 34b
S - 229bd 167b 880b 34b
V - 222cd 160bc 855c 33c
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 34 days      
C + 297a 234a 1110a 44a
S + 358bc 301bc 1305bc 53bc
V + 353b 295b 1291b 52c
C - 361bc 304bc 1317bc 53bc 
S - 365c 309c 1329c 54b
V - 360bc 303bc 1318bc 53bc 
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 41 days      
C + 396a 345a 1427a 58a
S + 429b 386b 1534b 63b
V + 467c 436c 1659c 69c
C - 479cd 452cd 1693cd 71cd 
S - 483d 457d 1710d 72d
V - 485d 458d 1711d 72d
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 48 days      
C + 516a 503a 1812a 77a
S + 511a 500a 1801a 76a
V + 594b 620b 2075b 89b
C - 581b 604b 2030b 87b
S - 576b 595b 2010b 86b
V - 590b 613b 2060b 88b
Trt 0.0013 0.0014 0.0014 0.0014 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0124 0.0075 0.0137 0.0107 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; g=gram; 
Trt=Treatment (C, S, V); Chall=Challenge (+, -) 
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TABLE 8:  Protein Gain (PG), Fat Gain (FG), Water Gain (WG), and Ash Gain (AG) for Male 
Broilers During Challenge Periods 
Treatment Challenge PG (g) FG (g) WG (g) AG (g) 
Age 20 days      
C + 22a 17a 67a 3.0a
S + 42b 33b 141b 6.0b
V + 28c 22c 95c 4.0c
C - 56d 42d 190d 8.0d
S - 52de 40d 176de 7.4de 
V - 47e 36b 164e 6.8e
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 27 days      
C + 30a 25a 110a 4.6a
S + 69bc 60b 242bc 10.2bc 
V + 62d 53c 219c 9.2b
C - 73b 64d 256b 10.9c
S - 71b 62d 252bc 10.7c
V - 64cd 55bc 227c 9.6b
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 34 days      
C + 28a 27a 101a 4.3a
S + 85bc 91bc 285bc 12.7bc 
V + 82c 87c 275c 12.2b
C - 91b 98b 308b 13.6c
S - 93b 99b 309b 13.8c
V - 89bc 95bc 301bc 13.3bc
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 41 days      
C + 9a 10a 25a 1.3a
S + 38b 47b 120b 5.7b
V + 78c 99c 250c 11.7c
C - 92d 117d 292cd 13.8d
S - 92d 118d 296d 13.9d
V - 96d 121d 301d 14.3d
Trt <0.0001 <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 <0.0001 
Age 48 days      
C + -4a -5a -23a -0.8a
S + -12a -12a -39a -1.7a
V + 73b 110b 238b 11.5b
C - 61b 94b 196b 9.6b
S - 54b 83b 171b 8.47b
V - 69b 102b 225b 10.8b
Trt 0.0012 0.0012 0.0012 0.0012 
Chall <0.0001 <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0124 0.0076 0.0142 0.0109 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; g=gram; 
Trt=Treatment (C, S, V); Chall=Challenge (+, -) 
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TABLE 9:  Protein, Fat, Water, and Ash Percent Content of Male Broilers After Challenge Periods 
Treatment Challenge Protein (%) Fat (%) Water (%) Ash (%) 
Age 20 days      
C + 16.7a 10.0a 69.6ac 2.41a
S + 16.8ab 10.4b 69.0ab 2.45bc
V + 16.8ab 10.3c 69.6c 2.44b
C - 16.9b 10.8d 68.4d 2.47c
S - 16.8ab 10.6d 68.6bd 2.46bc
V - 16.9b 10.6d 68.8bd 2.46bc 
Trt 0.5080 0.1093 0.1309 0.3562 
Chall 0.0393 <0.0001 <0.0001 0.0001 P value 
Trt*Chall 0.3131 <0.0001 0.2200 0.0297 
Age 27 days      
C + 17.0a 11.7a 66.7ab 2.51a
S + 17.2b 12.5b 66.2a 2.54b
V + 17.3bc 12.4b 66.6ab 2.54b
C - 17.2b 12.5bc 66.1a 2.54b
S - 17.4c 12.7c 67.0b 2.57c
V - 17.3bc 12.5bc 66.7ab 2.55bc 
Trt 0.0025 <0.0001 0.6245 0.0027 
Chall 0.0020 <0.0001 0.6547 0.0019 P value 
Trt*Chall 0.2993 <0.0001 0.0096 0.2364 
Age 34 days      
C + 17.3a 13.7a 64.7a 2.56ab 
S + 17.4ab 14.6bc 63.5bc 2.56ab 
V + 17.5ab 14.6b 64.0ab 2.57ab 
C - 17.3a 14.6b 63.2c 2.55a
S - 17.6b 14.8c 63.9abc 2.59b
V - 17.5ab 14.7bc 64.0ab 2.58ab 
Trt 0.0966 <0.0001 0.4844 0.1096 
Chall 0.4549 <0.0001 0.0896 0.4060 P value 
Trt*Chall 0.3433 <0.0001 0.0009 0.3815 
Age 41 days      
C + 17.5a 15.3a 63.2a 2.59a
S + 17.6a 15.8b 63.0a 2.60a
V + 17.4a 16.2c 62.0b 2.58a
C - 17.5a 16.5cd 62.0b 2.59a
S - 17.5a 16.6d 62.1b 2.60a
V - 17.5a 16.5d 61.7b 2.59a
Trt 0.5048 <0.0001 0.0117 0.4852 
Chall 0.9232 <0.0001 0.0002 0.5914 P value 
Trt*Chall 0.7063 0.0001 0.1660 0.8944 
Age 48 days      
C + 17.4ab 17.0a 61.4a 2.59ab 
S + 17.6b 17.0a 62.1a 2.61b
V + 17.3ac 18.0b 60.4b 2.59ab 
C - 17.2c 17.7b 60.1b 2.57a
S - 17.2ac 17.7b 60.2b 2.57a
V - 17.2ac 17.9b 60.1b 2.58ab 
Trt 0.3312 0.0136 0.0333 0.6046 
Chall 0.0010 0.0139 <0.0001 0.0193 P value 
Trt*Chall 0.3115 0.0883 0.0410 0.6339 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; Protein (%) = Protein 
(g)/Body Weight (g) X 100;  Fat (%) = Fat (g)/Body Weight (g) X 100; Water (%) = Water (g)/Body 
Weight (g) X 100;  Ash (%) = Ash (g)/Body Weight (g) X 100; Trt=Treatment (C, S, V); 
Chall=Challenge (+, -) 
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TABLE 10:  Heat Production (HP) per Metabolic Body Weight (HPMBW), Metabolizable Energy 
Consumption (MEc), and Heat Production per Kcal Metabolizable Energy (ME) Consumed 
(HPMEc) of Male Broilers During Challenge Periods 
Treatment Challenge HPMB (kcal/kg0.75) MEc (kcal) HPMEc 
Age 20 days     
C + 1120a 1025a 1.09a
S + 871b 1198b 0.73b
V + 968c 1061a 0.92c
C - 750bd 1320c 0.57d
S - 782d 1320c 0.60d
V - 795bd 1231b 0.65bd 
Trt 0.0048 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall 0.0001 <0.0001 <0.0001 
Age 27 days     
C + 1341a 1869a 0.72a
S + 1057bc 2207bc 0.48bcd 
V + 1075bc 2128b 0.51bd 
C - 1008b 2253c 0.45c
S - 1023b 2241c 0.46bc
V - 1148c 2236c 0.51d
Trt 0.0048 <0.0001 <0.0001 
Chall 0.0034 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 34 days     
C + 1204a 2318a 0.52a
S + 824b 2729b 0.30bc 
V + 916b 2768bc 0.33b
C - 853b 2876d 0.30bc 
S - 832b 2863cd 0.29c
V - 911b 2832cd 0.32bc 
Trt <0.0001 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 41 days     
C + 1157a 2301a 0.51a
S + 993b 2608b 0.39b
V + 801c 2980c 0.27c
C - 747c 3231d 0.23c
S - 769c 3316d 0.23c
V - 794c 3310d 0.24c
Trt 0.0006 <0.0001 <0.0001 
Chall <0.0001 <0.0001 <0.0001 P value 
Trt*Chall <0.0001 <0.0001 <0.0001 
Age 48 days     
C + 1167a 2593a 0.45a
S + 1151a 2615a 0.45a
V + 871b 3361b 0.26b
C - 828b 3417b 0.25b
S - 866b 3240b 0.28b
V - 880b 3303b 0.28b
0.2877 0.0079 0.0455 
0.0015 <0.0001 <0.0001 P value 
Trt 
Chall 
Trt*Chall 0.0769 0.0012 0.0063 
C = Control; S = Salinomycin; V = Vaccinated; + = Challenged; - = Unchallenged; HPMB= HP 
composition (HPc) /weight (kilograms)0.75; MEc=ME consumed; HPMEc=HPc/MEc; Trt=Treatment (C, 
S, V); Chall=Challenge (+, -); kcal=kilocalorie 
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TABLE 11:  Metabolizable Energy Consumption Reduction Due to Challenge (MEcr), 
Maintenance Energy Increase Due to Challenge (MC), and Total Caloric Cost of Challenge 
(TCC) of Male Broilers During Challenge Periods 
Treatment MEcr (kcal) MC (kcal) TCC (kcal) 
Age 20 days    
C 337+300a 280+308a 617+466a
S 121+300a 73+308a 194+466a
V 181+300a 158+308a 339+466a
Age 27 days    
C 335+300a 445+308a 780+466a
S -15+300b 80+308b 65+466b
V 109+300ab -76+308b 33+466b
Age 34 days    
C 560+300a 71+3082a 1272+466a
S 132+300b -33+308b 99+466b
V 22+300b 11+308b 33+466b
Age 41 days    
C 916+300a 1080+308a 1996+466a
S 786+300a 613+308b 1399+466b
V 222+300b -72+308c 150+466c
Age 48 days    
C 780+300a 460+308ab 1240+466a
S 511+300a 711+308a 1222+466a
V 113+300b 269+308b 382+466b
Trt <0.0001 <0.0001 <0.0001 
Age <0.0001 <0.0001 <0.0001 P value 
Trt*Age 0.0215 <0.0001 <0.0001 
C = Control; S = Salinomycin; V = Vaccinated; MEcr=Metabolizable energy consumed by 
unchallenged bird – Metabolizable energy consumed by challenged Bird; MC=(Metabolizable energy 
consumed - (protein gain*5.65)/0.67 + (fat gain*9.3)/0.87)) – body weight0.75 X 110 X 6) of challenged 
bird - (Metabolizable energy consumed - (protein gain*5.65)/0.67 + (fat gain*9.3)/0.87)) – body 
weight0.75 X 110 X 6) of unchallenged bird; TCC=MEcr + MC; Trt= Treatment (C, S, V) 
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FIGURE 1:  Treatment Effects on Challenge Period Feed Consumption Per Bird of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
89
FIGURE 2:  Treatment Effects on Challenge Period Feed Consumption Per Bird of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 3:  Treatment Effects on Challenge Period Live Weight of Unchallenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 4:  Treatment Effects on Challenge Period Live Weight of Challenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 5:  Treatment Effects on Challenge Period Average Daily Gain of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 6:  Treatment Effects on Challenge Period Average Daily Gain of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 7:  Treatment Effects on Challenge Period Body Weight Gain of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 8:  Treatment Effects on Challenge Period Body Weight Gain of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 9:  Treatment Effects on Challenge Period Feed Efficiency of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Gain to Feed (g/g)=Body 
weight gain in grams/Feed consumption in grams; g=grams 
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FIGURE 10:  Treatment Effects on Challenge Period Feed Efficiency of Challenged 
Birds
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Gain to Feed (g/g)=Body 
weight gain in grams/Feed consumption in grams; g=grams 
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FIGURE 11:  Treatment Effects on Upper Small Intestine Lesion Score of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 12:  Treatment Effects on Upper Small Intestine Lesion Score of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 13:  Treatment Effects on Middle Small Intestine Lesion Score of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 14:  Treatment Effects on Middle Small Intestine Lesion Score of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 15:  Treatment Effects on Cecal Lesion Score of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 16:  Treatment Effects on Cecal Lesion Score of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 17:  Treatment Effects on Eimeria Acervulina Lesion Score of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 18:  Treatment Effects on Eimeria Acervulina Lesion Score of Challenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 19:  Treatment Effects on Eimeria Maxima Lesion Score of Unchallenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 20:  Treatment Effects on Eimeria Maxima Lesion Score of Challenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 21:  Treatment Effects on Eimeria Tenella Lesion Score of Unchallenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 22:  Treatment Effects on Eimeria Tenella Lesion Score of Challenged 
Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Lesion scores range from 0 
(no lesions) to 4 (many lesions) 
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FIGURE 23:  Treatment Effects on Total Challenge Period Heat Production of 
Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalories 
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FIGURE 24:  Treatment Effects on Total Challenge Period Heat Production of 
Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalories 
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FIGURE 25:  Treatment Effects on Retained Energy of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalories 
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FIGURE 26:  Treatment Effects on Retained Energy of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalories 
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FIGURE 27:  Treatment Effects on Retained Energy Efficiency of Unchallenged 
Birds
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Retained Energy 
Efficiency=Retained Energy/Metabolizable Energy consumed 
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FIGURE 28:  Treatment Effects on Retained Energy Efficiency of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Retained Energy 
Efficiency=Retained Energy/Metabolizable Energy consumed 
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FIGURE 29:  Treatment Effects on Body Protein of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 30:  Treatment Effects on Body Protein of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 31:  Treatment Effects on Body Fat of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 32:  Treatment Effects on Body Fat of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 33:  Treatment Effects on Body Water of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 34:  Treatment Effects on Body Water of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 35:  Treatment Effects on Body Ash of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 36:  Treatment Effects on Body Ash of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; g=grams 
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FIGURE 37:  Treatment Effects on Percent Protein of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Protein (%)=Protein 
(grams)/Live Weight (grams) 
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FIGURE 38:  Treatment Effects on Percent Protein of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Protein (%)=Protein 
(grams)/Live Weight (grams) 
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FIGURE 39:  Treatment Effects on Percent Fat of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Fat (%)=Fat (grams)/Live 
Weight (grams) 
127
FIGURE 40:  Treatment Effects on Percent Fat of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Fat (%)=Fat (grams)/Live 
Weight (grams) 
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FIGURE 41:  Treatment Effects on Percent Water of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Water (%)=Water 
(grams)/Live Weight (grams) 
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FIGURE 42:  Treatment Effects on Percent Water of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Water (%)=Water 
(grams)/Live Weight (grams) 
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FIGURE 43:  Treatment Effects on Percent Ash of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Ash (%)=Ash (grams)/Live 
Weight (grams) 
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FIGURE 44:  Treatment Effects on Percent Ash of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; Ash (%)=Ash (grams)/Live 
Weight (grams) 
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FIRGURE 45:  Schering-Plough Quadrants of Performance of Broilers on a 
Vaccination Program Experiencing an Immune Challenge 
 
Q-1=Quadrant 1; Q-2=Quadrant 2; Q-3= Quadrant 3; Q-4=Quadrant 4 
 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
AGE IN DAYS
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Q-1 
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Q-2 
Performance Threshold 
Economic   
Threshold 
Litter Oocysts
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FIRGURE 46:  Schering-Plough Quadrants of Performance of Broilers on an 
Ionophore Program Experiencing an Immune Challenge 
Q-1=Quadrant 1; Q-2=Quadrant 2; Q-3= Quadrant 3; Q-4=Quadrant 4 
 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
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Litter Oocysts
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FIRGURE 47:  Schering-Plough Quadrants of Performance of Broilers of 
Subsequent Flocks on an Ionophore Program Experiencing an Immune Challenge 
Q-1=Quadrant 1; Q-2=Quadrant 2; Q-3= Quadrant 3; Q-4=Quadrant 4 
 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
AGE IN DAYS
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135
FIGURE 48:  Recorded Metabolizable Energy Consumption vs. Predicted 
Metabolizable Energy Consumption for Control Birds 
Kcal=kilocalorie; Chall=challenge group; +=challenged; - = unchallenged; 
ME=metabolizable energy; predicted ME consumption= 110 x body weight0.75 x 6 +
(protein gain x 5.65)/Kp + (fat gain x 9.3)/Kf; Kp=protein accretion efficiency constant 
(0.67); Kf=fat accretion efficiency constant (0.87) 
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FIGURE 49:  Recorded Metabolizable Energy Consumption vs. Predicted 
Metabolizable Energy Consumption for Salinomycin Birds 
Kcal=kilocalorie; Chall=challenge group; +=challenged; - = unchallenged; 
ME=metabolizable energy; predicted ME consumption= 110 x body weight0.75 x 6 +
(protein gain x 5.65)/Kp + (fat gain x 9.3)/Kf; Kp=protein accretion efficiency constant 
(0.67); Kf=fat accretion efficiency constant (0.87) 
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FIGURE 50:  Recorded Metabolizable Energy Consumption vs. Predicted 
Metabolizable Energy Consumption for Vaccinated Birds 
Kcal=kilocalorie; Chall=challenge group; +=challenged; - = unchallenged; 
ME=metabolizable energy; predicted ME consumption= 110 x body weight0.75 x 6 +
(protein gain x 5.65)/Kp + (fat gain x 9.3)/Kf; Kp=protein accretion efficiency constant 
(0.67); Kf=fat accretion efficiency constant (0.87) 
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FIGURE 51:  Treatment Effects on Heat Production (HP) per Metabolic Body 
Weight (MBW) of Unchallenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalorie; 
kg=kilogram; MBW=Body weight0.75 
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FIGURE 52:  Treatment Effects on Heat Production (HP) per Metabolic Body 
Weight (MBW) of Challenged Birds 
Trt=Treatment; C=Control; S=Salinomycin; V=Vaccinated; kcal=kilocalorie; 
kg=kilogram; MBW=Body weight0.75 
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